Central Core Myopathy

Mendelian MONDO:0007294 Pathograph 23 Congenital myopathy RYR1-related myopathy

Central core myopathy (central core disease, CCD) is a congenital myopathy caused predominantly by mutations in the RYR1 gene encoding the skeletal muscle ryanodine receptor (RyR1), the principal sarcoplasmic reticulum calcium release channel. It is characterized histopathologically by central cores — areas of sarcomeric disorganization and mitochondrial depletion running along the longitudinal axis of type 1 muscle fibers. Clinical features include proximal muscle weakness, hypotonia, delayed motor milestones, orthopaedic complications, and susceptibility to malignant hyperthermia. Inheritance is most commonly autosomal dominant with incomplete penetrance and variable expressivity, though autosomal recessive forms exist and tend to be more severe. First described by Shy and Magee in 1956, CCD was the first congenital myopathy defined by a specific histological abnormality.

Ask OpenScientist

Ask a research question about Central Core Myopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal dominant HP:0000006

Most cases of central core myopathy follow autosomal dominant inheritance with incomplete penetrance and variable expressivity. Dominant mutations are typically missense changes clustered in recognized mutational hotspot regions including the C-terminal transmembrane/pore-forming domain and tend to cause a milder phenotype.

Autosomal dominant inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE

Show evidence (2 references)

PMID:22473935 SUPPORT Human Clinical

"Dominant mutations, typically missense, were frequently located in recognized mutational hotspot regions, while recessive mutations were distributed throughout the entire coding sequence. "

Large cohort study of 71 families confirms that dominant RYR1 mutations are typically missense and cluster in hotspot regions.

PMID:8220422 SUPPORT Human Clinical

"Central core disease (CCD) is a morphologically distinct, autosomal dominant myopathy with variable clinical features. "

The landmark 1993 Nature Genetics paper establishing the RYR1 link describes CCD as autosomal dominant with variable features.

Autosomal recessive HP:0000007

Autosomal recessive forms of central core myopathy tend to be more severe, with earlier onset, greater weakness, and more functional limitations. Extraocular and bulbar muscle involvement is almost exclusively observed in recessive cases. Recessive mutations are distributed throughout the RYR1 coding sequence and often include nonsense and splice mutations expected to result in reduced RyR1 protein expression.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:22473935 SUPPORT Human Clinical

"As a group, dominant mutations were associated with milder phenotypes; patients with recessive inheritance had earlier onset, more weakness, and functional limitations. Extraocular and bulbar muscle involvement was almost exclusively observed in the recessive group. "

This large cohort study of 71 families (35 dominant, 36 recessive) demonstrates the clinical distinction between dominant and recessive RYR1-related myopathies.

◆

Subtypes

Autosomal dominant central core disease

Dominantly inherited RYR1-related central core disease is typically caused by heterozygous missense variants in RYR1 hotspot regions. It often presents from infancy or childhood with mild-to-moderate static or slowly progressive proximal weakness, delayed motor development, orthopedic complications, and clinically important malignant hyperthermia susceptibility.

Show evidence (2 references)

PMID:22473935 SUPPORT Human Clinical

"Dominant mutations, typically missense, were frequently located in recognized mutational hotspot regions, while recessive mutations were distributed throughout the entire coding sequence."

This large RYR1 cohort distinguishes dominant hotspot missense variants from recessive variants distributed throughout the gene.

PMID:33458581 SUPPORT Human Clinical

"Dominantly inherited RYR1-related central core disease is characterized by mild to moderate muscle weakness presenting from infancy to childhood."

The review supports the typical milder childhood-onset dominant CCD clinical pattern.

Autosomal recessive central core disease

Recessive central core disease due to biallelic RYR1 variants is more clinically heterogeneous and tends to be more severe, with earlier onset, greater weakness, functional limitation, and enrichment for extraocular, bulbar, and respiratory involvement.

Show evidence (2 references)

PMID:22473935 SUPPORT Human Clinical

"As a group, dominant mutations were associated with milder phenotypes; patients with recessive inheritance had earlier onset, more weakness, and functional limitations."

The cohort directly contrasts recessive RYR1 disease with the milder dominant group.

PMID:22473935 SUPPORT Human Clinical

"Extraocular and bulbar muscle involvement was almost exclusively observed in the recessive group."

This supports subtype-aware assignment of ophthalmoplegia and bulbar/facial involvement to recessive RYR1-related myopathy.

⚙

Pathophysiology

Dominant RYR1 missense hotspot variants

Dominant central core myopathy is usually caused by heterozygous RYR1 missense variants concentrated in recognized mutational hotspot regions. These variants alter RyR1 channel gating rather than simply reducing gene dosage, creating an upstream mutation class that feeds into abnormal sarcoplasmic-reticulum calcium release, congenital myopathy, and malignant hyperthermia susceptibility.

Skeletal muscle fiber CL:0008002

RYR1 hgnc:10483 ⚠ ABNORMAL

Regulation of SR calcium release GO:0010880 ⚠ ABNORMAL

Downstream

Abnormal RyR1 calcium release channel function Missense hotspot variants alter RyR1 channel conformation and calcium release behavior.

Anesthetic-triggered malignant hyperthermia mechanism Dominant RYR1 missense variants create the allelic substrate for malignant hyperthermia susceptibility in CCD.

Show evidence (2 references)

PMID:22473935 SUPPORT Human Clinical

"Dominant mutations, typically missense, were frequently located in recognized mutational hotspot regions, while recessive mutations were distributed throughout the entire coding sequence. "

Defines the dominant mutation class as mainly missense variants in RYR1 hotspot regions.

PMID:16917943 SUPPORT Human Clinical

"The majority of gene mutations reported are missense changes identified in cases of MH and CCD. "

Supports missense RYR1 variants as the common mutation type shared by central core disease and malignant hyperthermia.

Recessive RYR1 reduced-expression variants

Recessive RYR1-related myopathy often reflects biallelic variants spread across the coding sequence, including nonsense and splice variants expected to reduce RyR1 protein abundance. This mutation class is associated with earlier onset, greater weakness, more functional limitation, and extraocular or bulbar involvement compared with dominant disease.

Skeletal muscle fiber CL:0008002

RYR1 hgnc:10483 ↓ DECREASED

Downstream

RyR1 deficiency and excitation-contraction uncoupling Reduced RyR1 protein compromises the channel complex needed for normal skeletal muscle excitation-contraction coupling.

Show evidence (2 references)

PMID:22473935 SUPPORT Human Clinical

"Recessive mutations included nonsense and splice mutations expected to result in reduced RyR1 protein. "

Supports reduced RyR1 protein abundance as a recessive mutation-to- mechanism path.

PMID:22473935 SUPPORT Human Clinical

"As a group, dominant mutations were associated with milder phenotypes; patients with recessive inheritance had earlier onset, more weakness, and functional limitations. "

Links recessive inheritance to the more severe clinical phenotype trajectory.

Abnormal RyR1 calcium release channel function

RYR1 mutations alter the function of the ryanodine receptor, the principal calcium release channel of the sarcoplasmic reticulum in skeletal muscle. Dominant missense variants often produce hypersensitive or leaky RyR1 channels with lowered threshold for sarcoplasmic reticulum calcium release, while recessive mutations frequently result in reduced RyR1 protein expression or excitation-contraction coupling uncoupling. Both mechanisms disrupt the DHPR-RyR1 signaling axis and calcium homeostasis in skeletal muscle fibers.

Skeletal muscle fiber CL:0008002 Slow muscle cell (type I fiber) CL:0000189

RYR1 hgnc:10483 ⚠ ABNORMAL

Regulation of SR calcium release GO:0010880 Calcium ion homeostasis GO:0055074 Regulation of skeletal muscle contraction by calcium signaling GO:0014722

Downstream

Excitation-contraction coupling impairment Abnormal RyR1 calcium release disrupts the calcium signal that links membrane depolarization to skeletal muscle contraction.

Mitochondrial depletion and oxidative metabolism deficiency in cores Chronic calcium-homeostasis disturbance contributes to focal metabolic and structural disruption within type 1 fibers.

Anesthetic-triggered malignant hyperthermia mechanism RyR1 channel instability provides the mechanism for exaggerated calcium release during malignant-hyperthermia-triggering anesthesia.

Show evidence (3 references)

PMID:17504518 SUPPORT Human Clinical

"Altered excitability and/or changes in calcium homeostasis within muscle cells due to mutation-induced conformational changes of the RyR protein are considered the main pathogenetic mechanism(s). "

Comprehensive Orphanet review of CCD establishing that mutation-induced conformational changes in RyR1 leading to altered calcium homeostasis are the main pathogenetic mechanism.

PMID:16917943 SUPPORT Human Clinical

"The RYR1 gene encodes the skeletal muscle isoform ryanodine receptor and is fundamental to the process of excitation-contraction coupling and skeletal muscle calcium homeostasis. "

Review of RYR1 mutations in MH and CCD confirming the role of RYR1 in excitation-contraction coupling and calcium homeostasis.

PMID:16917943 SUPPORT In Vitro

"In vitro analysis has confirmed that alteration of normal calcium homeostasis is a functional consequence of some of these changes. "

Confirms functional evidence that RYR1 mutations alter calcium homeostasis through in vitro studies.

RyR1 deficiency and excitation-contraction uncoupling

Recessive RYR1 variants that lower RyR1 expression reduce the functional channel pool available at the triad. The resulting excitation-contraction uncoupling causes reduced calcium-triggered contraction and explains the more severe congenital weakness, ophthalmoplegia, bulbar involvement, and respiratory compromise observed in recessive disease.

Skeletal muscle fiber CL:0008002

RYR1 hgnc:10483 ↓ DECREASED

Regulation of skeletal muscle contraction by calcium signaling GO:0014722 ↕ DYSREGULATED Skeletal muscle contraction GO:0003009 ↓ DECREASED

Downstream

Reduced skeletal muscle force generation Uncoupling lowers calcium-dependent activation of contraction in skeletal muscle fibers.

External ophthalmoplegia Extraocular involvement is a recessive RYR1-enriched phenotype in the cohort data.

Myopathic facies Bulbar and facial weakness are linked to recessive RYR1 disease severity.

Respiratory insufficiency Severe recessive impairment of skeletal muscle contraction can involve respiratory muscle groups.

Show evidence (2 references)

PMID:22473935 SUPPORT Human Clinical

"Recessive mutations included nonsense and splice mutations expected to result in reduced RyR1 protein. "

Supports the reduced-expression mechanism for recessive RYR1-related myopathy.

PMID:29391587 SUPPORT Human Clinical

"To date, congenital myopathies have been attributed to mutations in over 20 genes, which encode proteins implicated in skeletal muscle Ca2+ homeostasis, excitation-contraction coupling, thin-thick filament assembly and interactions, and other mechanisms. "

Places RYR1-related congenital myopathy in the broader mechanism class of excitation-contraction coupling and calcium-homeostasis disorders.

Excitation-contraction coupling impairment

RyR1 dysfunction disrupts the DHPR-RyR1 calcium-release signal that couples sarcolemmal depolarization to actin-myosin force generation. This provides the central mechanistic bridge from RYR1 mutation classes to congenital weakness, hypotonia, delayed motor development, respiratory involvement, and core formation.

Skeletal muscle fiber CL:0008002 Type I muscle fiber CL:0002211

Regulation of skeletal muscle contraction by calcium signaling GO:0014722 ↕ DYSREGULATED Skeletal muscle contraction GO:0003009 ↓ DECREASED

Downstream

Reduced skeletal muscle force generation Impaired calcium release reduces calcium-dependent actin-myosin force generation.

Mitochondrial depletion and oxidative metabolism deficiency in cores Persistent calcium-homeostasis disturbance contributes to type 1 fiber core formation and oxidative enzyme loss.

Show evidence (2 references)

PMID:16917943 SUPPORT Human Clinical

"The RYR1 gene encodes the skeletal muscle isoform ryanodine receptor and is fundamental to the process of excitation-contraction coupling and skeletal muscle calcium homeostasis. "

Establishes RyR1 as the core channel linking mutation to excitation-contraction coupling and calcium homeostasis.

PMID:29391587 SUPPORT Human Clinical

"RYR1 mutations are the most frequent genetic cause, and CCD and MmD are the most common subgroups. "

Confirms that RYR1-mediated excitation-contraction coupling defects are a major causal class among congenital myopathies.

Reduced skeletal muscle force generation

Impaired RyR1-dependent calcium signaling reduces activation of skeletal muscle contraction. The functional consequence is congenital hypotonia, delayed motor milestones, predominantly proximal weakness, orthopedic complications from chronic weakness and hypotonia, and respiratory insufficiency in more severe disease.

Skeletal muscle fiber CL:0008002

Skeletal muscle contraction GO:0003009 ↓ DECREASED

Downstream

Proximal muscle weakness Reduced force output in skeletal muscle fibers produces predominantly proximal weakness.

Neonatal hypotonia Congenital weakness lowers resting tone in infancy.

Delayed gross motor development Hypotonia and proximal weakness delay attainment of early gross motor milestones.

Axial muscle weakness Reduced contractile force in paraspinal and trunk-stabilizing muscles manifests clinically as axial weakness.

Scoliosis Chronic axial and proximal weakness contributes to orthopedic complications including scoliosis.

Congenital hip dislocation Congenital hypotonia and weakness contribute to hip instability and other orthopedic complications.

Respiratory insufficiency Severe skeletal muscle weakness may involve respiratory muscles.

Show evidence (2 references)

PMID:29391587 SUPPORT Human Clinical

"Pronounced weakness in axial and proximal muscle groups is a common feature, and involvement of extraocular, cardiorespiratory and/or distal muscles can implicate specific genetic defects. "

Links congenital myopathy mechanisms to axial/proximal weakness and possible cardiorespiratory involvement.

PMID:17504518 SUPPORT Human Clinical

"CCD typically presents in infancy with hypotonia and motor developmental delay and is characterized by predominantly proximal weakness pronounced in the hip girdle "

Establishes the main downstream clinical consequences of impaired skeletal muscle force generation in CCD.

Mitochondrial depletion and oxidative metabolism deficiency in cores

The central cores that define this myopathy histologically represent focal regions of myofibrillar disorganization with depletion of mitochondria and absence of oxidative enzyme activity. Cores run along the longitudinal axis of type 1 muscle fibers and are visualized as unstained regions on NADH-TR and cytochrome oxidase histochemistry. Mitochondrial calcium overload from dysfunctional RyR1 channels generates energetic strain and oxidative stress, contributing to the ultrastructural disorganization characteristic of cores.

Skeletal muscle fiber CL:0008002

Response to oxidative stress GO:0006979 Intracellular calcium ion homeostasis GO:0006874

Downstream

Central core regions in muscle fibers Focal mitochondrial depletion and loss of oxidative enzyme activity define central core regions on muscle biopsy.

Reduced skeletal muscle force generation Core regions combine sarcomeric disorganization and metabolic deficiency, contributing to reduced contractile performance.

Show evidence (2 references)

PMID:17504518 PARTIAL Human Clinical

"Central core disease (CCD) is an inherited neuromuscular disorder characterised by central cores on muscle biopsy and clinical features of a congenital myopathy. "

Establishes the defining histopathological feature of CCD as central cores on muscle biopsy.

PMID:22473935 SUPPORT Human Clinical

"Histopathological findings frequently feature central cores or multi-minicores, more rarely, type 1 predominance/uniformity, fiber-type disproportion, increased internal nucleation, and fatty and connective tissue. "

Confirms that central cores are frequent histopathological findings in RYR1-related myopathies.

Anesthetic-triggered malignant hyperthermia mechanism

RYR1 mutations predispose to malignant hyperthermia (MH), a pharmacogenetic disorder triggered by volatile anesthetic agents and succinylcholine. The susceptible RyR1 channel exhibits exaggerated calcium release in response to these triggers, causing sustained muscle contraction, hypermetabolism, rhabdomyolysis, and potentially fatal hyperthermia. CCD and MHS are allelic conditions and a single RYR1 mutation may result in either or both phenotypes.

Muscle contraction GO:0006936 ↑ INCREASED Calcium ion homeostasis GO:0055074 ↕ DYSREGULATED

Downstream

Malignant hyperthermia susceptibility RYR1-triggered excessive calcium release is the mechanism underlying the malignant hyperthermia susceptibility phenotype.

Show evidence (2 references)

PMID:17504518 SUPPORT Human Clinical

"CCD and MHS are allelic conditions both due to (predominantly dominant) mutations in the skeletal muscle ryanodine receptor (RYR1) gene, encoding the principal skeletal muscle sarcoplasmic reticulum calcium release channel (RyR1). "

Establishes that CCD and MHS are allelic conditions caused by mutations in the same RYR1 gene.

PMID:8220423 SUPPORT Human Clinical

"One of these mutations was also detected in an unrelated MH pedigree whose members are asymptomatic of CCD. The data suggest a model to explain how a single mutation may result in two apparently distinct clinical phenotypes. "

Demonstrates that the same RYR1 mutation can cause CCD in one family and isolated MH susceptibility in another, establishing the allelic relationship.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Eye 1

External ophthalmoplegia HP_0040284 External ophthalmoplegia HP:0000544

Show evidence (1 reference)

PMID:22473935 SUPPORT Human Clinical

"Extraocular and bulbar muscle involvement was almost exclusively observed in the recessive group. "

Extraocular involvement (ophthalmoplegia) is almost exclusively seen in recessive RYR1-related myopathies.

Head and Neck 1

Myopathic facies HP_0040283 Myopathic facies HP:0002058

Show evidence (1 reference)

PMID:22473935 SUPPORT Human Clinical

"Extraocular and bulbar muscle involvement was almost exclusively observed in the recessive group. "

Demonstrates that facial and bulbar involvement is characteristic of recessive RYR1-related myopathies.

Limbs 1

Congenital hip dislocation HP_0040282 Congenital hip dislocation HP:0001374

Show evidence (1 reference)

PMID:17504518 PARTIAL Human Clinical

"orthopaedic complications are common "

Congenital hip dislocation is one of the common orthopaedic complications in CCD.

Metabolism 1

Malignant hyperthermia susceptibility HP_0040282 Malignant hyperthermia HP:0002047

Show evidence (2 references)

PMID:17504518 SUPPORT Human Clinical

"malignant hyperthermia susceptibility (MHS) is a frequent complication "

Establishes MHS as a frequent complication of CCD.

PMID:8220423 SUPPORT Human Clinical

"Central core disease (CCD) of muscle is an inherited myopathy which is closely associated with malignant hyperthermia (MH) in humans. "

Confirms the close association between CCD and MH.

Musculoskeletal 4

Proximal muscle weakness HP_0040281 Proximal muscle weakness HP:0003701

Show evidence (2 references)

PMID:17504518 SUPPORT Human Clinical

"CCD typically presents in infancy with hypotonia and motor developmental delay and is characterized by predominantly proximal weakness pronounced in the hip girdle "

Comprehensive review establishing proximal weakness pronounced in the hip girdle as a characteristic feature of CCD.

PMID:29391587 PARTIAL Human Clinical

"Pronounced weakness in axial and proximal muscle groups is a common feature "

Major Nature Reviews Neurology review confirming axial and proximal weakness as common in congenital myopathies including CCD.

Neonatal hypotonia HP_0040282 Neonatal hypotonia HP:0001319

Show evidence (1 reference)

PMID:17504518 SUPPORT Human Clinical

"CCD typically presents in infancy with hypotonia and motor developmental delay "

Establishes infantile hypotonia as a typical presenting feature of CCD.

Scoliosis HP_0040282 Scoliosis HP:0002650

Show evidence (1 reference)

PMID:17504518 PARTIAL Human Clinical

"orthopaedic complications are common "

Orthopaedic complications including scoliosis are identified as common in CCD.

Exertional rhabdomyolysis HP_0040283 Rhabdomyolysis HP:0003201

Show evidence (1 reference)

PMID:33458581 PARTIAL Human Clinical

"RYR1-related malignant hyperthermia susceptibility is allelic to central core disease and has also been described as a common cause of induced and episodic phenotypes such as exertional rhabdomyolysis or periodic paralysis, which present throughout life."

This is modeled with partial support because the source frames exertional rhabdomyolysis as an allelic RYR1/MH-related episodic phenotype rather than as a universal central core disease manifestation.

Nervous System 1

Delayed gross motor development HP_0040282 Delayed gross motor development HP:0002194

Show evidence (1 reference)

PMID:17504518 SUPPORT Human Clinical

"CCD typically presents in infancy with hypotonia and motor developmental delay "

Motor developmental delay is identified as a typical presenting feature.

Respiratory 1

Respiratory insufficiency HP_0040283 Respiratory insufficiency HP:0002093

Show evidence (1 reference)

PMID:29391587 PARTIAL Human Clinical

"involvement of extraocular, cardiorespiratory and/or distal muscles can implicate specific genetic defects "

Cardiorespiratory involvement is noted as a feature that can occur in congenital myopathies.

Other 4

Central core regions in muscle fibers HP_0040280 Central core regions in muscle fibers HP:0030230

Show evidence (2 references)

PMID:17504518 SUPPORT Human Clinical

"Central core disease (CCD) is an inherited neuromuscular disorder characterised by central cores on muscle biopsy and clinical features of a congenital myopathy. "

Establishes central cores on muscle biopsy as a defining disease feature.

PMID:22473935 SUPPORT Human Clinical

Supports central cores as frequent biopsy findings in the RYR1-related myopathy cohort.

Type 1 muscle fiber predominance HP_0040281 Type 1 muscle fiber predominance HP:0003803

Show evidence (1 reference)

PMID:22473935 SUPPORT Human Clinical

Same large-cohort histopathology summary explicitly identifies type 1 fiber predominance/uniformity as a feature of RYR1-related myopathy biopsies.

Axial muscle weakness HP_0040282 Axial muscle weakness HP:0003327

Show evidence (2 references)

PMID:29391587 SUPPORT Human Clinical

"Pronounced weakness in axial and proximal muscle groups is a common feature "

Major Nature Reviews Neurology review identifies axial weakness as a common feature of congenital myopathies including RYR1-related CCD.

PMID:19959667 SUPPORT Model Organism

"IT/+ mice exhibit a slowly progressive congenital myopathy, with neonatal respiratory stress, skeletal muscle weakness, impaired mobility, dorsal kyphosis, and hind limb paralysis. "

I4895T mouse model recapitulates dorsal kyphosis, consistent with axial muscle weakness contributing to the postural deformity.

Abnormal foot morphology HP_0040283 Abnormal foot morphology HP:0001760

Show evidence (1 reference)

PMID:33458581 SUPPORT Human Clinical

"musculoskeletal deformities including congenital hip dislocation, kyphoscoliosis, pes cavus, pes planus, and thoracic deformities"

The core-myopathy review lists foot deformities among orthopedic complications of central core disease.

🧬

Genetic Associations

RYR1 mutations (Causative)

Gene: RYR1 hgnc:10483

Show evidence (4 references)

PMID:8220422 SUPPORT Human Clinical

"The only amino acid substitution found was an Arg2434His mutation, resulting from the substitution of A for G7301. This mutation was linked to CCD with a lod score of 4.8 at a recombinant fraction of 0.0 in 16 informative meioses in a 130 member family, suggesting a causal relationship to CCD. "

Landmark 1993 Nature Genetics paper that first identified a specific RYR1 mutation (Arg2434His) as causative of central core disease through linkage analysis in a large family.

PMID:16917943 SUPPORT Human Clinical

"Mapping to chromosome 19q13.2, the gene comprises 106 exons and encodes a protein of 5,038 amino acids. Mutations in the gene have been found in association with several diseases: the pharmacogenetic disorder, malignant hyperthermia (MH); and three congenital myopathies, including central core..."

Comprehensive review of RYR1 mutations establishing the gene structure and its association with CCD, MH, and other congenital myopathies.

PMID:22473935 SUPPORT Human Clinical

"Ryanodine receptor 1 (RYR1) mutations are a common cause of congenital myopathies associated with both dominant and recessive inheritance. "

Large cohort study confirming RYR1 mutations as a common cause of congenital myopathies with both inheritance patterns.

+ 1 more reference

💊

Medical Actions

Avoidance of malignant hyperthermia triggers

Action: chemical exposure avoidance MAXO:0000071

Strict avoidance of volatile anesthetic agents (halothane, sevoflurane, desflurane, isoflurane) and depolarizing neuromuscular blocking agents (succinylcholine) during surgical procedures. Total intravenous anesthesia (TIVA) with agents such as propofol is recommended. Management must anticipate susceptibility to potentially life-threatening reactions to general anaesthesia.

Show evidence (2 references)

PMID:17504518 SUPPORT Human Clinical

"Management is mainly supportive and has to anticipate susceptibility to potentially life-threatening reactions to general anaesthesia. "

Establishes the critical importance of anesthetic precautions in CCD management.

PMID:20301325 SUPPORT Human Clinical

"Avoid potent inhalation anesthetics and succinylcholine."

GeneReviews specifies the anesthetic trigger agents that should be avoided in malignant hyperthermia susceptibility.

Perioperative malignant hyperthermia emergency planning

Action: preventative therapy MAXO:0000017

Patients should carry medical alert documentation for malignant hyperthermia susceptibility, inform surgeons and anesthesiologists before any procedure requiring anesthesia, use prepared non-triggering anesthetic protocols, and have an emergency plan that includes immediate access to dantrolene and MHAUS consultation resources.

Target Phenotypes: Malignant hyperthermia HP:0002047

Show evidence (3 references)

PMID:20301325 SUPPORT Human Clinical

"Individuals with MHS should carry proper identification (e.g., MedicAlert® bracelet) as to their susceptibility."

GeneReviews supports written/bracelet alerting for MH susceptibility.

PMID:33458581 SUPPORT Human Clinical

"all patients subjected to general anesthesia require preoperative anesthetic consultation and planning to ensure that a nontriggering anesthetic technique is used."

Core-myopathy review supports preoperative anesthesia planning for all central core disease patients undergoing general anesthesia.

PMID:20301325 SUPPORT Human Clinical

"communication with Malignant Hyperthermia Association of the US (MHAUS) helpline"

GeneReviews includes MHAUS helpline communication in successful acute malignant hyperthermia management.

Dantrolene for malignant hyperthermia

Action: Dantrolene therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: dantrolene CHEBI:4317

Dantrolene sodium is the specific treatment for acute malignant hyperthermia episodes. It acts by inhibiting calcium release from the sarcoplasmic reticulum via the ryanodine receptor. Dantrolene should be immediately available whenever a susceptible patient undergoes anesthesia.

Show evidence (1 reference)

PMID:20301325 SUPPORT Human Clinical

"Administration of intravenous dantrolene sodium (initial dose of 2.5 mg/kg) as early as possible during an MH episode."

GeneReviews identifies early intravenous dantrolene as targeted therapy for malignant hyperthermia episodes.

Physical therapy and rehabilitation

Action: Physical therapy Ontology label: physical therapy MAXO:0000011

Regular physical therapy focusing on maintaining range of motion, preventing contractures, and maximizing functional capacity. Exercise programs should be tailored to individual ability.

Show evidence (1 reference)

PMID:33458581 SUPPORT Human Clinical

"Core elements of treatment include physical therapy, orthopedic interventions, management of respiratory complications, and feeding problems."

This review identifies physical therapy as a core management component for core myopathies including central core disease.

Orthopedic management

Action: orthopedic procedure MAXO:0000477

Surgical and conservative management of musculoskeletal complications including scoliosis, hip dislocation, and foot deformities. Bracing and assistive devices may be needed.

Show evidence (2 references)

PMID:33458581 SUPPORT Human Clinical

"Children should be monitored for the development of scoliosis and other skeletal deformities."

This supports active orthopedic monitoring during growth.

PMID:33458581 SUPPORT Human Clinical

"Congenital dislocation and dysplasia of the hip require orthopedic treatment."

This directly supports orthopedic management for hip complications.

Respiratory surveillance and support

Action: supportive care MAXO:0000950

Respiratory function should be followed over time, especially in recessive or severe disease and when scoliosis or spinal rigidity is present. Serial pulmonary function testing and sleep studies can detect subclinical nocturnal hypoventilation; respiratory support is managed according to respiratory-muscle involvement.

Target Phenotypes: Respiratory insufficiency HP:0002093

Show evidence (1 reference)

PMID:33458581 SUPPORT Human Clinical

"Respiratory function should be monitored with serial pulmonary function tests, and where indicated, sleep studies."

This supports respiratory surveillance for subclinical or progressive respiratory involvement.

Genetic counseling

Action: Genetic counseling Ontology label: genetic counseling MAXO:0000079

Genetic counseling for affected families should discuss autosomal dominant and autosomal recessive inheritance, recurrence risk, variant interpretation, central core disease severity spectrum, and implications for family members regarding malignant hyperthermia susceptibility.

Show evidence (2 references)

PMID:17504518 PARTIAL Human Clinical

"Mutational analysis of the RYR1 gene may provide genetic confirmation of the diagnosis. "

Supports the role of genetic testing and counseling in CCD diagnosis and family management.

PMID:20301325 SUPPORT Human Clinical

"It is appropriate to clarify the status of at-risk relatives of an individual diagnosed with MHS to identify those who also have an increased susceptibility to MH and thus would benefit from avoiding anesthetic agents that increase the risk for an MH episode."

GeneReviews supports family counseling and risk clarification for malignant hyperthermia susceptibility.

Family cascade testing for malignant hyperthermia risk

Action: genetic testing MAXO:0000127

First-degree relatives and other at-risk family members should be offered targeted familial RYR1 variant testing when the pathogenic variant is known. If the molecular cause is unknown or testing is inconclusive, muscle biopsy with contracture testing can clarify MH susceptibility.

Target Phenotypes: Malignant hyperthermia HP:0002047

Show evidence (1 reference)

PMID:20301325 SUPPORT Human Clinical

"Evaluations include: multigene panel testing (if the MHS-related causative variant in the family is known) and muscle biopsy and contracture testing (if the MHS-causative pathogenic variant in the family is not known"

GeneReviews supports cascade molecular testing or biopsy/contracture testing depending on whether the familial MHS variant is known.

{ }

Source YAML

click to show

name: Central Core Myopathy
creation_date: '2026-02-13T18:01:36Z'
updated_date: '2026-04-26T19:00:00Z'
category: Mendelian
description: >
  Central core myopathy (central core disease, CCD) is a congenital myopathy caused
  predominantly by mutations in the RYR1 gene encoding the skeletal muscle ryanodine
  receptor (RyR1), the principal sarcoplasmic reticulum calcium release channel.
  It is characterized histopathologically by central cores — areas of sarcomeric
  disorganization and mitochondrial depletion running along the longitudinal axis
  of type 1 muscle fibers. Clinical features include proximal muscle weakness,
  hypotonia, delayed motor milestones, orthopaedic complications, and susceptibility
  to malignant hyperthermia. Inheritance is most commonly autosomal dominant with
  incomplete penetrance and variable expressivity, though autosomal recessive forms
  exist and tend to be more severe. First described by Shy and Magee in 1956, CCD
  was the first congenital myopathy defined by a specific histological abnormality.
disease_term:
  preferred_term: central core myopathy
  term:
    id: MONDO:0007294
    label: central core myopathy
parents:
- Congenital myopathy
- RYR1-related myopathy
has_subtypes:
- name: AD-CCD
  display_name: Autosomal dominant central core disease
  description: >-
    Dominantly inherited RYR1-related central core disease is typically caused
    by heterozygous missense variants in RYR1 hotspot regions. It often presents
    from infancy or childhood with mild-to-moderate static or slowly progressive
    proximal weakness, delayed motor development, orthopedic complications, and
    clinically important malignant hyperthermia susceptibility.
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dominant mutations, typically missense, were frequently located in
      recognized mutational hotspot regions, while recessive mutations were
      distributed throughout the entire coding sequence.
    explanation: >-
      This large RYR1 cohort distinguishes dominant hotspot missense variants
      from recessive variants distributed throughout the gene.
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dominantly inherited RYR1-related central core disease is characterized by
      mild to moderate muscle weakness presenting from infancy to childhood.
    explanation: >-
      The review supports the typical milder childhood-onset dominant CCD
      clinical pattern.
- name: AR-CCD
  display_name: Autosomal recessive central core disease
  description: >-
    Recessive central core disease due to biallelic RYR1 variants is more
    clinically heterogeneous and tends to be more severe, with earlier onset,
    greater weakness, functional limitation, and enrichment for extraocular,
    bulbar, and respiratory involvement.
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As a group, dominant mutations were associated with milder phenotypes;
      patients with recessive inheritance had earlier onset, more weakness,
      and functional limitations.
    explanation: >-
      The cohort directly contrasts recessive RYR1 disease with the milder
      dominant group.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Extraocular and bulbar muscle involvement was almost exclusively observed
      in the recessive group.
    explanation: >-
      This supports subtype-aware assignment of ophthalmoplegia and bulbar/facial
      involvement to recessive RYR1-related myopathy.
prevalence:
- population: All-age populations
  percentage: 0.37 per 100,000
  notes: >-
    Population studies usually report prevalence for core myopathies or
    congenital myopathies as groups rather than for central core myopathy
    alone. Meta-analysis estimated pooled all-age prevalence for core myopathy
    at 0.37 per 100,000, and an Orphanet review noted that central core disease
    is probably the most common congenital myopathy.
  evidence:
  - reference: PMID:34795634
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "0.37 (95% CI 0.21-0.53) for core myopathy"
    explanation: This meta-analysis provides the best available pooled population estimate for the core-myopathy group that includes central core myopathy.
  - reference: PMID:17504518
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence is unknown but the condition is probably more common than other congenital myopathies."
    explanation: This disease-specific review clarifies that central core disease itself lacks a separate direct population estimate but is likely the commonest congenital myopathy.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >
    Most cases of central core myopathy follow autosomal dominant inheritance
    with incomplete penetrance and variable expressivity. Dominant mutations
    are typically missense changes clustered in recognized mutational hotspot
    regions including the C-terminal transmembrane/pore-forming domain and
    tend to cause a milder phenotype.
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Dominant mutations, typically missense, were frequently located in
      recognized mutational hotspot regions, while recessive mutations were
      distributed throughout the entire coding sequence.
    explanation: >
      Large cohort study of 71 families confirms that dominant RYR1 mutations
      are typically missense and cluster in hotspot regions.
  - reference: PMID:8220422
    reference_title: "A mutation in the human ryanodine receptor gene associated with central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Central core disease (CCD) is a morphologically distinct, autosomal
      dominant myopathy with variable clinical features.
    explanation: >
      The landmark 1993 Nature Genetics paper establishing the RYR1 link
      describes CCD as autosomal dominant with variable features.
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Autosomal recessive forms of central core myopathy tend to be more severe,
    with earlier onset, greater weakness, and more functional limitations.
    Extraocular and bulbar muscle involvement is almost exclusively observed
    in recessive cases. Recessive mutations are distributed throughout the
    RYR1 coding sequence and often include nonsense and splice mutations
    expected to result in reduced RyR1 protein expression.
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      As a group, dominant mutations were associated with milder phenotypes;
      patients with recessive inheritance had earlier onset, more weakness,
      and functional limitations. Extraocular and bulbar muscle involvement
      was almost exclusively observed in the recessive group.
    explanation: >
      This large cohort study of 71 families (35 dominant, 36 recessive)
      demonstrates the clinical distinction between dominant and recessive
      RYR1-related myopathies.
pathophysiology:
- name: Dominant RYR1 missense hotspot variants
  description: >
    Dominant central core myopathy is usually caused by heterozygous RYR1
    missense variants concentrated in recognized mutational hotspot regions.
    These variants alter RyR1 channel gating rather than simply reducing gene
    dosage, creating an upstream mutation class that feeds into abnormal
    sarcoplasmic-reticulum calcium release, congenital myopathy, and malignant
    hyperthermia susceptibility.
  gene:
    preferred_term: RYR1
    description: >
      Ryanodine receptor 1, the skeletal muscle sarcoplasmic reticulum calcium
      release channel mutated in dominant central core myopathy.
    modifier: ABNORMAL
    term:
      id: hgnc:10483
      label: RYR1
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: Regulation of SR calcium release
    modifier: ABNORMAL
    term:
      id: GO:0010880
      label: regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Dominant mutations, typically missense, were frequently located in
      recognized mutational hotspot regions, while recessive mutations were
      distributed throughout the entire coding sequence.
    explanation: >
      Defines the dominant mutation class as mainly missense variants in RYR1
      hotspot regions.
  - reference: PMID:16917943
    reference_title: "Mutations in RYR1 in malignant hyperthermia and central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      The majority of gene mutations reported are missense changes identified
      in cases of MH and CCD.
    explanation: >
      Supports missense RYR1 variants as the common mutation type shared by
      central core disease and malignant hyperthermia.
  downstream:
  - target: Abnormal RyR1 calcium release channel function
    description: >
      Missense hotspot variants alter RyR1 channel conformation and calcium
      release behavior.
    causal_link_type: DIRECT
  - target: Anesthetic-triggered malignant hyperthermia mechanism
    description: >
      Dominant RYR1 missense variants create the allelic substrate for
      malignant hyperthermia susceptibility in CCD.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered RyR1 channel gating
    - exaggerated calcium release after anesthetic trigger
- name: Recessive RYR1 reduced-expression variants
  description: >
    Recessive RYR1-related myopathy often reflects biallelic variants spread
    across the coding sequence, including nonsense and splice variants expected
    to reduce RyR1 protein abundance. This mutation class is associated with
    earlier onset, greater weakness, more functional limitation, and extraocular
    or bulbar involvement compared with dominant disease.
  gene:
    preferred_term: RYR1
    description: >
      Ryanodine receptor 1, whose reduced expression can impair skeletal muscle
      excitation-contraction coupling in recessive central core myopathy.
    modifier: DECREASED
    term:
      id: hgnc:10483
      label: RYR1
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Recessive mutations included nonsense and splice mutations expected to
      result in reduced RyR1 protein.
    explanation: >
      Supports reduced RyR1 protein abundance as a recessive mutation-to-
      mechanism path.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      As a group, dominant mutations were associated with milder phenotypes;
      patients with recessive inheritance had earlier onset, more weakness,
      and functional limitations.
    explanation: >
      Links recessive inheritance to the more severe clinical phenotype
      trajectory.
  downstream:
  - target: RyR1 deficiency and excitation-contraction uncoupling
    description: >
      Reduced RyR1 protein compromises the channel complex needed for normal
      skeletal muscle excitation-contraction coupling.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced RyR1 protein
    - impaired DHPR-RyR1 coupling
- name: Abnormal RyR1 calcium release channel function
  description: >
    RYR1 mutations alter the function of the ryanodine receptor, the principal
    calcium release channel of the sarcoplasmic reticulum in skeletal muscle.
    Dominant missense variants often produce hypersensitive or leaky RyR1
    channels with lowered threshold for sarcoplasmic reticulum calcium release,
    while recessive mutations frequently result in reduced RyR1 protein
    expression or excitation-contraction coupling uncoupling. Both mechanisms
    disrupt the DHPR-RyR1 signaling axis and calcium homeostasis in skeletal
    muscle fibers.
  gene:
    preferred_term: RYR1
    description: >
      Ryanodine receptor 1, a large homotetrameric calcium release channel of
      the sarcoplasmic reticulum that is fundamental to excitation-contraction
      coupling and skeletal muscle calcium homeostasis.
    modifier: ABNORMAL
    term:
      id: hgnc:10483
      label: RYR1
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  - preferred_term: Slow muscle cell (type I fiber)
    term:
      id: CL:0000189
      label: slow muscle cell
  biological_processes:
  - preferred_term: Regulation of SR calcium release
    term:
      id: GO:0010880
      label: regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
  - preferred_term: Calcium ion homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  - preferred_term: Regulation of skeletal muscle contraction by calcium signaling
    term:
      id: GO:0014722
      label: regulation of skeletal muscle contraction by calcium ion signaling
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Altered excitability and/or changes in calcium homeostasis within muscle
      cells due to mutation-induced conformational changes of the RyR protein
      are considered the main pathogenetic mechanism(s).
    explanation: >
      Comprehensive Orphanet review of CCD establishing that mutation-induced
      conformational changes in RyR1 leading to altered calcium homeostasis
      are the main pathogenetic mechanism.
  - reference: PMID:16917943
    reference_title: "Mutations in RYR1 in malignant hyperthermia and central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      The RYR1 gene encodes the skeletal muscle isoform ryanodine receptor
      and is fundamental to the process of excitation-contraction coupling and
      skeletal muscle calcium homeostasis.
    explanation: >
      Review of RYR1 mutations in MH and CCD confirming the role of RYR1 in
      excitation-contraction coupling and calcium homeostasis.
  - reference: PMID:16917943
    reference_title: "Mutations in RYR1 in malignant hyperthermia and central core disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >
      In vitro analysis has confirmed that alteration of normal calcium
      homeostasis is a functional consequence of some of these changes.
    explanation: >
      Confirms functional evidence that RYR1 mutations alter calcium
      homeostasis through in vitro studies.
  downstream:
  - target: Excitation-contraction coupling impairment
    description: >
      Abnormal RyR1 calcium release disrupts the calcium signal that links
      membrane depolarization to skeletal muscle contraction.
    causal_link_type: DIRECT
  - target: Mitochondrial depletion and oxidative metabolism deficiency in cores
    description: >
      Chronic calcium-homeostasis disturbance contributes to focal metabolic
      and structural disruption within type 1 fibers.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered intracellular calcium homeostasis
    - mitochondrial stress
  - target: Anesthetic-triggered malignant hyperthermia mechanism
    description: >
      RyR1 channel instability provides the mechanism for exaggerated calcium
      release during malignant-hyperthermia-triggering anesthesia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - volatile anesthetic or succinylcholine exposure
    - uncontrolled sarcoplasmic reticulum calcium release
- name: RyR1 deficiency and excitation-contraction uncoupling
  description: >
    Recessive RYR1 variants that lower RyR1 expression reduce the functional
    channel pool available at the triad. The resulting excitation-contraction
    uncoupling causes reduced calcium-triggered contraction and explains the
    more severe congenital weakness, ophthalmoplegia, bulbar involvement, and
    respiratory compromise observed in recessive disease.
  gene:
    preferred_term: RYR1
    description: >
      Ryanodine receptor 1 deficiency reduces the skeletal muscle calcium
      release channel pool needed for excitation-contraction coupling.
    modifier: DECREASED
    term:
      id: hgnc:10483
      label: RYR1
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: Regulation of skeletal muscle contraction by calcium signaling
    modifier: DYSREGULATED
    term:
      id: GO:0014722
      label: regulation of skeletal muscle contraction by calcium ion signaling
  - preferred_term: Skeletal muscle contraction
    modifier: DECREASED
    term:
      id: GO:0003009
      label: skeletal muscle contraction
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Recessive mutations included nonsense and splice mutations expected to
      result in reduced RyR1 protein.
    explanation: >
      Supports the reduced-expression mechanism for recessive RYR1-related
      myopathy.
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      To date, congenital myopathies have been attributed to mutations in over
      20 genes, which encode proteins implicated in skeletal muscle Ca2+
      homeostasis, excitation-contraction coupling, thin-thick filament
      assembly and interactions, and other mechanisms.
    explanation: >
      Places RYR1-related congenital myopathy in the broader mechanism class of
      excitation-contraction coupling and calcium-homeostasis disorders.
  downstream:
  - target: Reduced skeletal muscle force generation
    description: >
      Uncoupling lowers calcium-dependent activation of contraction in skeletal
      muscle fibers.
    causal_link_type: DIRECT
  - target: External ophthalmoplegia
    description: >
      Extraocular involvement is a recessive RYR1-enriched phenotype in the
      cohort data.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - severe recessive RYR1-related myopathy
    - extraocular muscle weakness
  - target: Myopathic facies
    description: >
      Bulbar and facial weakness are linked to recessive RYR1 disease severity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - severe recessive RYR1-related myopathy
    - bulbar or facial muscle weakness
  - target: Respiratory insufficiency
    description: >
      Severe recessive impairment of skeletal muscle contraction can involve
      respiratory muscle groups.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - respiratory muscle weakness
- name: Excitation-contraction coupling impairment
  description: >
    RyR1 dysfunction disrupts the DHPR-RyR1 calcium-release signal that couples
    sarcolemmal depolarization to actin-myosin force generation. This provides
    the central mechanistic bridge from RYR1 mutation classes to congenital
    weakness, hypotonia, delayed motor development, respiratory involvement, and
    core formation.
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  - preferred_term: Type I muscle fiber
    term:
      id: CL:0002211
      label: type I muscle cell
  biological_processes:
  - preferred_term: Regulation of skeletal muscle contraction by calcium signaling
    modifier: DYSREGULATED
    term:
      id: GO:0014722
      label: regulation of skeletal muscle contraction by calcium ion signaling
  - preferred_term: Skeletal muscle contraction
    modifier: DECREASED
    term:
      id: GO:0003009
      label: skeletal muscle contraction
  evidence:
  - reference: PMID:16917943
    reference_title: "Mutations in RYR1 in malignant hyperthermia and central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      The RYR1 gene encodes the skeletal muscle isoform ryanodine receptor
      and is fundamental to the process of excitation-contraction coupling and
      skeletal muscle calcium homeostasis.
    explanation: >
      Establishes RyR1 as the core channel linking mutation to
      excitation-contraction coupling and calcium homeostasis.
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      RYR1 mutations are the most frequent genetic cause, and CCD and MmD are
      the most common subgroups.
    explanation: >
      Confirms that RYR1-mediated excitation-contraction coupling defects are a
      major causal class among congenital myopathies.
  downstream:
  - target: Reduced skeletal muscle force generation
    description: >
      Impaired calcium release reduces calcium-dependent actin-myosin force
      generation.
    causal_link_type: DIRECT
  - target: Mitochondrial depletion and oxidative metabolism deficiency in cores
    description: >
      Persistent calcium-homeostasis disturbance contributes to type 1 fiber
      core formation and oxidative enzyme loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered intracellular calcium homeostasis
    - local mitochondrial dysfunction
- name: Reduced skeletal muscle force generation
  description: >
    Impaired RyR1-dependent calcium signaling reduces activation of skeletal
    muscle contraction. The functional consequence is congenital hypotonia,
    delayed motor milestones, predominantly proximal weakness, orthopedic
    complications from chronic weakness and hypotonia, and respiratory
    insufficiency in more severe disease.
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: Skeletal muscle contraction
    modifier: DECREASED
    term:
      id: GO:0003009
      label: skeletal muscle contraction
  evidence:
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Pronounced weakness in axial and proximal muscle groups is a common
      feature, and involvement of extraocular, cardiorespiratory and/or distal
      muscles can implicate specific genetic defects.
    explanation: >
      Links congenital myopathy mechanisms to axial/proximal weakness and
      possible cardiorespiratory involvement.
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      CCD typically presents in infancy with hypotonia and motor developmental
      delay and is characterized by predominantly proximal weakness pronounced
      in the hip girdle
    explanation: >
      Establishes the main downstream clinical consequences of impaired
      skeletal muscle force generation in CCD.
  downstream:
  - target: Proximal muscle weakness
    description: >
      Reduced force output in skeletal muscle fibers produces predominantly
      proximal weakness.
    causal_link_type: DIRECT
  - target: Neonatal hypotonia
    description: >
      Congenital weakness lowers resting tone in infancy.
    causal_link_type: DIRECT
  - target: Delayed gross motor development
    description: >
      Hypotonia and proximal weakness delay attainment of early gross motor
      milestones.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neonatal hypotonia
    - proximal weakness
  - target: Axial muscle weakness
    description: >
      Reduced contractile force in paraspinal and trunk-stabilizing muscles
      manifests clinically as axial weakness.
    causal_link_type: DIRECT
  - target: Scoliosis
    description: >
      Chronic axial and proximal weakness contributes to orthopedic
      complications including scoliosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - axial muscle weakness
    - altered spinal loading
  - target: Congenital hip dislocation
    description: >
      Congenital hypotonia and weakness contribute to hip instability and other
      orthopedic complications.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - neonatal hypotonia
    - periarticular muscle weakness
  - target: Respiratory insufficiency
    description: >
      Severe skeletal muscle weakness may involve respiratory muscles.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - respiratory muscle weakness
- name: Mitochondrial depletion and oxidative metabolism deficiency in cores
  description: >
    The central cores that define this myopathy histologically represent focal
    regions of myofibrillar disorganization with depletion of mitochondria and
    absence of oxidative enzyme activity. Cores run along the longitudinal axis
    of type 1 muscle fibers and are visualized as unstained regions on NADH-TR
    and cytochrome oxidase histochemistry. Mitochondrial calcium overload from
    dysfunctional RyR1 channels generates energetic strain and oxidative stress,
    contributing to the ultrastructural disorganization characteristic of cores.
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: Intracellular calcium ion homeostasis
    term:
      id: GO:0006874
      label: intracellular calcium ion homeostasis
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Central core disease (CCD) is an inherited neuromuscular disorder
      characterised by central cores on muscle biopsy and clinical features
      of a congenital myopathy.
    explanation: >
      Establishes the defining histopathological feature of CCD as central
      cores on muscle biopsy.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Histopathological findings frequently feature central cores or
      multi-minicores, more rarely, type 1 predominance/uniformity,
      fiber-type disproportion, increased internal nucleation, and fatty and
      connective tissue.
    explanation: >
      Confirms that central cores are frequent histopathological findings in
      RYR1-related myopathies.
  downstream:
  - target: Central core regions in muscle fibers
    description: >
      Focal mitochondrial depletion and loss of oxidative enzyme activity
      define central core regions on muscle biopsy.
    causal_link_type: DIRECT
  - target: Reduced skeletal muscle force generation
    description: >
      Core regions combine sarcomeric disorganization and metabolic deficiency,
      contributing to reduced contractile performance.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - sarcomeric disorganization
    - oxidative metabolism deficiency
- name: Anesthetic-triggered malignant hyperthermia mechanism
  description: >
    RYR1 mutations predispose to malignant hyperthermia (MH), a pharmacogenetic
    disorder triggered by volatile anesthetic agents and succinylcholine. The
    susceptible RyR1 channel exhibits exaggerated calcium release in response
    to these triggers, causing sustained muscle contraction, hypermetabolism,
    rhabdomyolysis, and potentially fatal hyperthermia. CCD and MHS are allelic
    conditions and a single RYR1 mutation may result in either or both
    phenotypes.
  biological_processes:
  - preferred_term: Muscle contraction
    modifier: INCREASED
    term:
      id: GO:0006936
      label: muscle contraction
  - preferred_term: Calcium ion homeostasis
    modifier: DYSREGULATED
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      CCD and MHS are allelic conditions both due to (predominantly dominant)
      mutations in the skeletal muscle ryanodine receptor (RYR1) gene,
      encoding the principal skeletal muscle sarcoplasmic reticulum calcium
      release channel (RyR1).
    explanation: >
      Establishes that CCD and MHS are allelic conditions caused by mutations
      in the same RYR1 gene.
  - reference: PMID:8220423
    reference_title: "Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      One of these mutations was also detected in an unrelated MH pedigree
      whose members are asymptomatic of CCD. The data suggest a model to
      explain how a single mutation may result in two apparently distinct
      clinical phenotypes.
    explanation: >
      Demonstrates that the same RYR1 mutation can cause CCD in one family
      and isolated MH susceptibility in another, establishing the allelic
      relationship.
  downstream:
  - target: Malignant hyperthermia susceptibility
    description: >
      RYR1-triggered excessive calcium release is the mechanism underlying the
      malignant hyperthermia susceptibility phenotype.
    causal_link_type: DIRECT
phenotypes:
- name: Proximal muscle weakness
  description: >
    Predominantly proximal muscle weakness affecting hip girdle and shoulder
    girdle muscles is a hallmark feature. Weakness is pronounced in the hip
    girdle and is typically static or only slowly progressive.
  frequency: HP_0040281
  phenotype_term:
    preferred_term: Proximal muscle weakness
    term:
      id: HP:0003701
      label: Proximal muscle weakness
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      CCD typically presents in infancy with hypotonia and motor developmental
      delay and is characterized by predominantly proximal weakness pronounced
      in the hip girdle
    explanation: >
      Comprehensive review establishing proximal weakness pronounced in the
      hip girdle as a characteristic feature of CCD.
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Pronounced weakness in axial and proximal muscle groups is a common
      feature
    explanation: >
      Major Nature Reviews Neurology review confirming axial and proximal
      weakness as common in congenital myopathies including CCD.
- name: Neonatal hypotonia
  description: >
    Hypotonia present from birth is a common presenting feature, often leading
    to the initial clinical evaluation. Severity ranges from mild to marked,
    with recessive forms tending to be more severe.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Neonatal hypotonia
    term:
      id: HP:0001319
      label: Neonatal hypotonia
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      CCD typically presents in infancy with hypotonia and motor
      developmental delay
    explanation: >
      Establishes infantile hypotonia as a typical presenting feature of CCD.
- name: Delayed gross motor development
  description: >
    Motor development is typically delayed, with late achievement of sitting,
    standing, and independent ambulation. Most patients eventually achieve
    independent walking, though this may be delayed.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Delayed gross motor development
    term:
      id: HP:0002194
      label: Delayed gross motor development
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      CCD typically presents in infancy with hypotonia and motor
      developmental delay
    explanation: >
      Motor developmental delay is identified as a typical presenting feature.
- name: Central core regions in muscle fibers
  description: >
    Muscle biopsy shows well-demarcated central core regions in skeletal muscle
    fibers, reflecting focal sarcomeric disorganization with mitochondrial and
    oxidative-enzyme depletion. This is the defining histopathological feature
    of central core myopathy.
  frequency: HP_0040280
  phenotype_term:
    preferred_term: Central core regions in muscle fibers
    term:
      id: HP:0030230
      label: Central core regions in muscle fibers
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Central core disease (CCD) is an inherited neuromuscular disorder
      characterised by central cores on muscle biopsy and clinical features
      of a congenital myopathy.
    explanation: >
      Establishes central cores on muscle biopsy as a defining disease feature.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Histopathological findings frequently feature central cores or
      multi-minicores, more rarely, type 1 predominance/uniformity,
      fiber-type disproportion, increased internal nucleation, and fatty and
      connective tissue.
    explanation: >
      Supports central cores as frequent biopsy findings in the RYR1-related
      myopathy cohort.
- name: Type 1 muscle fiber predominance
  description: >
    Skeletal muscle biopsy frequently shows predominance or near-uniformity
    of type 1 (slow oxidative) fibers, with type 2 fibers reduced in number
    and often atrophic. The selective involvement reflects the higher RyR1
    abundance and oxidative-metabolism dependence of type 1 fibers, which
    are most affected by RyR1-driven Ca2+ leak and mitochondrial damage.
    Type 1 fiber predominance/uniformity is a recognized accompanying biopsy
    pattern alongside the central cores in RYR1-related myopathy.
  frequency: HP_0040281
  phenotype_term:
    preferred_term: Type 1 muscle fiber predominance
    term:
      id: HP:0003803
      label: Type 1 muscle fiber predominance
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Histopathological findings frequently feature central cores or
      multi-minicores, more rarely, type 1 predominance/uniformity,
      fiber-type disproportion, increased internal nucleation, and fatty and
      connective tissue.
    explanation: >
      Same large-cohort histopathology summary explicitly identifies type 1
      fiber predominance/uniformity as a feature of RYR1-related myopathy
      biopsies.
- name: Axial muscle weakness
  description: >
    Weakness of paraspinal and trunk-stabilizing muscles occurs in a
    substantial minority of patients alongside the predominantly proximal
    pattern. Axial weakness contributes to scoliosis risk and postural
    deformity (kyphosis). It is reported as a common feature of congenital
    myopathies of EC-coupling, including RYR1-related disease.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Axial muscle weakness
    term:
      id: HP:0003327
      label: Axial muscle weakness
  evidence:
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Pronounced weakness in axial and proximal muscle groups is a common
      feature
    explanation: >
      Major Nature Reviews Neurology review identifies axial weakness as a
      common feature of congenital myopathies including RYR1-related CCD.
  - reference: PMID:19959667
    reference_title: "Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      IT/+ mice exhibit a slowly progressive congenital myopathy, with
      neonatal respiratory stress, skeletal muscle weakness, impaired
      mobility, dorsal kyphosis, and hind limb paralysis.
    explanation: >
      I4895T mouse model recapitulates dorsal kyphosis, consistent with
      axial muscle weakness contributing to the postural deformity.
- name: Scoliosis
  description: >
    Scoliosis is a common orthopaedic complication that may require surgical
    correction in severe cases.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      orthopaedic complications are common
    explanation: >
      Orthopaedic complications including scoliosis are identified as common
      in CCD.
- name: Congenital hip dislocation
  description: >
    Congenital hip dislocation is a characteristic orthopaedic complication
    and may be the presenting feature of the disease.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Congenital hip dislocation
    term:
      id: HP:0001374
      label: Congenital hip dislocation
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      orthopaedic complications are common
    explanation: >
      Congenital hip dislocation is one of the common orthopaedic
      complications in CCD.
- name: Abnormal foot morphology
  description: >-
    Foot deformities, including pes cavus and pes planus, can occur as
    orthopedic complications in central core disease.
  frequency: HP_0040283
  phenotype_term:
    preferred_term: Abnormal foot morphology
    term:
      id: HP:0001760
      label: Abnormal foot morphology
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      musculoskeletal deformities including congenital hip dislocation,
      kyphoscoliosis, pes cavus, pes planus, and thoracic deformities
    explanation: >-
      The core-myopathy review lists foot deformities among orthopedic
      complications of central core disease.
- name: Malignant hyperthermia susceptibility
  description: >
    Susceptibility to malignant hyperthermia episodes triggered by volatile
    anesthetics or depolarizing muscle relaxants is a frequent and potentially
    life-threatening complication requiring precautionary measures for all
    surgical procedures.
  frequency: HP_0040282
  phenotype_term:
    preferred_term: Malignant hyperthermia
    term:
      id: HP:0002047
      label: Malignant hyperthermia
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      malignant hyperthermia susceptibility (MHS) is a frequent complication
    explanation: >
      Establishes MHS as a frequent complication of CCD.
  - reference: PMID:8220423
    reference_title: "Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Central core disease (CCD) of muscle is an inherited myopathy which is
      closely associated with malignant hyperthermia (MH) in humans.
    explanation: >
      Confirms the close association between CCD and MH.
- name: Exertional rhabdomyolysis
  description: >-
    Rhabdomyolysis can occur as an exertional or heat-related episodic phenotype
    in RYR1-related malignant hyperthermia susceptibility, which is allelic to
    central core disease.
  frequency: HP_0040283
  phenotype_term:
    preferred_term: Rhabdomyolysis
    term:
      id: HP:0003201
      label: Rhabdomyolysis
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RYR1-related malignant hyperthermia susceptibility is allelic to central
      core disease and has also been described as a common cause of induced and
      episodic phenotypes such as exertional rhabdomyolysis or periodic
      paralysis, which present throughout life.
    explanation: >-
      This is modeled with partial support because the source frames
      exertional rhabdomyolysis as an allelic RYR1/MH-related episodic phenotype
      rather than as a universal central core disease manifestation.
- name: Myopathic facies
  description: >
    Mild facial weakness may be present, more commonly in autosomal recessive
    forms. Extraocular and bulbar muscle involvement is almost exclusively
    observed in the recessive group.
  frequency: HP_0040283
  phenotype_term:
    preferred_term: Myopathic facies
    term:
      id: HP:0002058
      label: Myopathic facies
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Extraocular and bulbar muscle involvement was almost exclusively
      observed in the recessive group.
    explanation: >
      Demonstrates that facial and bulbar involvement is characteristic
      of recessive RYR1-related myopathies.
- name: External ophthalmoplegia
  description: >
    External ophthalmoplegia is observed primarily in autosomal recessive
    forms of RYR1-related myopathy.
  frequency: HP_0040284
  phenotype_term:
    preferred_term: External ophthalmoplegia
    term:
      id: HP:0000544
      label: External ophthalmoplegia
  evidence:
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Extraocular and bulbar muscle involvement was almost exclusively
      observed in the recessive group.
    explanation: >
      Extraocular involvement (ophthalmoplegia) is almost exclusively
      seen in recessive RYR1-related myopathies.
- name: Respiratory insufficiency
  description: >
    Variable respiratory involvement may occur, particularly in more severe
    recessive forms, sometimes requiring respiratory support.
  frequency: HP_0040283
  phenotype_term:
    preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  evidence:
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      involvement of extraocular, cardiorespiratory and/or distal muscles
      can implicate specific genetic defects
    explanation: >
      Cardiorespiratory involvement is noted as a feature that can occur
      in congenital myopathies.
genetic:
- name: RYR1 mutations
  association: Causative
  gene_term:
    preferred_term: RYR1
    description: >
      Ryanodine receptor 1, encoding a homotetrameric calcium release channel
      of 5,038 amino acids. Mapping to chromosome 19q13.2 and comprising 106
      exons, it is the principal skeletal muscle sarcoplasmic reticulum calcium
      release channel fundamental to excitation-contraction coupling.
    term:
      id: hgnc:10483
      label: RYR1
  notes: >
    RYR1 is the major causative gene for CCD. Over 300 pathogenic variants
    have been identified. Dominant mutations are typically missense changes
    clustered in recognized hotspot regions including the C-terminal
    pore-forming domain. Recessive mutations are distributed throughout the
    entire coding sequence and include nonsense and splice mutations expected
    to result in reduced RyR1 protein. RYR1 mutations are also the most
    frequent genetic cause of congenital myopathies overall.
  evidence:
  - reference: PMID:8220422
    reference_title: "A mutation in the human ryanodine receptor gene associated with central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      The only amino acid substitution found was an Arg2434His mutation,
      resulting from the substitution of A for G7301. This mutation was
      linked to CCD with a lod score of 4.8 at a recombinant fraction of
      0.0 in 16 informative meioses in a 130 member family, suggesting a
      causal relationship to CCD.
    explanation: >
      Landmark 1993 Nature Genetics paper that first identified a specific
      RYR1 mutation (Arg2434His) as causative of central core disease through
      linkage analysis in a large family.
  - reference: PMID:16917943
    reference_title: "Mutations in RYR1 in malignant hyperthermia and central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Mapping to chromosome 19q13.2, the gene comprises 106 exons and
      encodes a protein of 5,038 amino acids. Mutations in the gene have
      been found in association with several diseases: the pharmacogenetic
      disorder, malignant hyperthermia (MH); and three congenital myopathies,
      including central core disease (CCD), multiminicore disease (MmD), and
      in an isolated case of a congenital myopathy characterized on histology
      by cores and rods.
    explanation: >
      Comprehensive review of RYR1 mutations establishing the gene structure
      and its association with CCD, MH, and other congenital myopathies.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Ryanodine receptor 1 (RYR1) mutations are a common cause of congenital
      myopathies associated with both dominant and recessive inheritance.
    explanation: >
      Large cohort study confirming RYR1 mutations as a common cause of
      congenital myopathies with both inheritance patterns.
  - reference: PMID:29391587
    reference_title: "Congenital myopathies: disorders of excitation-contraction coupling and muscle contraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      RYR1 mutations are the most frequent genetic cause, and CCD and MmD
      are the most common subgroups.
    explanation: >
      Nature Reviews Neurology review confirming RYR1 as the most frequent
      genetic cause of congenital myopathies.
diagnosis:
- name: Clinical neuromuscular assessment
  description: >-
    Evaluation starts with congenital or early-onset myopathy features including
    neonatal hypotonia, delayed motor milestones, proximal or axial weakness,
    orthopedic complications, and family history. Dominant disease is often
    mild-to-moderate, while recessive disease can present with severe neonatal,
    bulbar, ophthalmoplegic, or respiratory involvement.
  diagnosis_term:
    preferred_term: physical examination
    term:
      id: MAXO:0000527
      label: physical examination
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CCD typically presents in infancy with hypotonia and motor developmental
      delay and is characterized by predominantly proximal weakness pronounced
      in the hip girdle
    explanation: >-
      This defines the core clinical presentation that should prompt diagnostic
      evaluation for central core disease.
- name: Muscle biopsy and oxidative histochemistry
  description: >-
    Muscle biopsy should evaluate hematoxylin/eosin and modified trichrome
    morphology, oxidative enzyme stains such as NADH-TR and COX/SDH, fiber type,
    and ultrastructure. Diagnostic findings include well-demarcated cores in
    type 1 fibers, absent oxidative enzyme activity in core regions,
    mitochondrial depletion, and often type 1 fiber predominance or uniformity.
  diagnosis_term:
    preferred_term: biopsy of muscle tissue
    term:
      id: MAXO:0000387
      label: biopsy of muscle tissue
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathological hallmark of central core disease is the presence of
      well-demarcated cores (round or oval shaped regions within a muscle fiber
      that lack oxidative enzyme activity on histochemical stains) within type 1
      muscle fibers (Fig. 3).
    explanation: >-
      The review identifies well-demarcated oxidative-enzyme-negative cores in
      type 1 fibers as the diagnostic biopsy hallmark.
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the presence of cores as the predominant pathological feature in the
      biopsy establishes the diagnosis of central core disease.
    explanation: >-
      This directly supports muscle biopsy as a diagnostic criterion when cores
      are the predominant pathologic feature.
- name: RYR1 molecular genetic testing
  description: >-
    Molecular testing should sequence RYR1 comprehensively and include copy
    number/deletion-duplication analysis when available, because dominant
    hotspot variants and recessive variants distributed throughout the gene can
    both cause central core disease. Variant interpretation should be integrated
    with clinical, biopsy, and muscle MRI findings.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in the ryanodine gene can be identified in more than 90% of
      patients with central core disease when all parts of the RYR1 are
      carefully sequenced
    explanation: >-
      This supports comprehensive RYR1 sequencing as a high-yield molecular
      diagnostic test for central core disease.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Dominant mutations, typically missense, were frequently located in recognized mutational hotspot regions, while recessive mutations were distributed throughout the entire coding sequence."
    explanation: >-
      The dominant/recessive variant distribution supports broad RYR1 testing
      rather than hotspot-only testing.
  - reference: PMID:22473935
    reference_title: "Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      interpretation of genetic results in the context of clinical,
      histological, and muscle magnetic resonance imaging findings is essential.
    explanation: >-
      Variant interpretation should be integrated with the clinical, biopsy, and
      imaging phenotype.
- name: Serum creatine kinase and EMG/NCS assessment
  description: >-
    Serum CK is usually normal or mildly elevated, while EMG/NCS can help
    exclude denervation disorders and may be normal or mildly myopathic. These
    ancillary studies support classification and differential diagnosis but do
    not replace biopsy or molecular testing.
  diagnosis_term:
    preferred_term: electromyography procedure
    term:
      id: MAXO:0035091
      label: electromyography procedure
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Serum creatine kinase is usually normal or mildly elevated.
    explanation: >-
      CK is useful as an ancillary laboratory feature and is usually normal or
      only mildly elevated in core myopathies.
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EMG is typically normal or shows myopathic features, with short-duration,
      small-amplitude, polyphasic motor unit potentials.
    explanation: >-
      EMG/NCS supports differential diagnosis by excluding denervation disorders
      and documenting normal or myopathic patterns.
- name: Muscle imaging to guide diagnosis
  description: >-
    Muscle MRI or ultrasound can demonstrate selective muscle involvement,
    support RYR1-related pattern recognition, guide biopsy-site selection, and
    help interpret variants when biopsy or genetic findings are equivocal.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: MAXO:0000424
      label: magnetic resonance imaging procedure
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      muscle MRI may show a characteristic pattern of selective muscle
      involvement and aid the diagnosis in cases with equivocal
      histopathological findings.
    explanation: >-
      Disease-specific review supports muscle MRI as an aid to diagnosis when
      biopsy findings are equivocal.
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Muscle imaging (ultrasonography and MRI) may be useful in diagnosis
      demonstrating a characteristic pattern of selective muscle involvement,
      which may be used in conjunction with clinical features to guide genetic
      testing.
    explanation: >-
      Muscle imaging supports diagnostic pattern recognition and genetic testing
      strategy.
- name: Malignant hyperthermia susceptibility evaluation
  description: >-
    Patients with central core disease should be treated as at risk for
    malignant hyperthermia. Risk evaluation includes review of prior anesthetic
    reactions, family history, RYR1 variant interpretation, and in vitro
    contracture testing with halothane and caffeine when molecular diagnosis is
    absent, uncertain, or needed for at-risk relatives.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      malignant hyperthermia susceptibility (MHS) is a frequent complication
    explanation: >-
      The disease-specific review supports MH-risk evaluation in central core
      disease; GeneReviews supplies the specific IVCT/contracture-testing
      method.
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of MHS is established with in vitro muscle contracture
      testing by measuring the contracture responses of biopsied muscle samples
      to halothane and graded concentrations of caffeine.
    explanation: >-
      GeneReviews specifies the standard contracture-test approach for MH
      susceptibility evaluation.
treatments:
- name: Avoidance of malignant hyperthermia triggers
  description: >
    Strict avoidance of volatile anesthetic agents (halothane, sevoflurane,
    desflurane, isoflurane) and depolarizing neuromuscular blocking agents
    (succinylcholine) during surgical procedures. Total intravenous anesthesia
    (TIVA) with agents such as propofol is recommended. Management must
    anticipate susceptibility to potentially life-threatening reactions to
    general anaesthesia.
  treatment_term:
    preferred_term: chemical exposure avoidance
    term:
      id: MAXO:0000071
      label: chemical exposure avoidance
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Management is mainly supportive and has to anticipate susceptibility to
      potentially life-threatening reactions to general anaesthesia.
    explanation: >
      Establishes the critical importance of anesthetic precautions in CCD
      management.
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Avoid potent inhalation anesthetics and succinylcholine.
    explanation: >-
      GeneReviews specifies the anesthetic trigger agents that should be avoided
      in malignant hyperthermia susceptibility.
- name: Perioperative malignant hyperthermia emergency planning
  description: >-
    Patients should carry medical alert documentation for malignant
    hyperthermia susceptibility, inform surgeons and anesthesiologists before
    any procedure requiring anesthesia, use prepared non-triggering anesthetic
    protocols, and have an emergency plan that includes immediate access to
    dantrolene and MHAUS consultation resources.
  treatment_term:
    preferred_term: preventative therapy
    term:
      id: MAXO:0000017
      label: preventative therapy
  target_phenotypes:
  - preferred_term: Malignant hyperthermia
    term:
      id: HP:0002047
      label: Malignant hyperthermia
  evidence:
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with MHS should carry proper identification (e.g., MedicAlert®
      bracelet) as to their susceptibility.
    explanation: >-
      GeneReviews supports written/bracelet alerting for MH susceptibility.
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      all patients subjected to general anesthesia require preoperative
      anesthetic consultation and planning to ensure that a nontriggering
      anesthetic technique is used.
    explanation: >-
      Core-myopathy review supports preoperative anesthesia planning for all
      central core disease patients undergoing general anesthesia.
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: communication with Malignant Hyperthermia Association of the US (MHAUS) helpline
    explanation: >-
      GeneReviews includes MHAUS helpline communication in successful acute
      malignant hyperthermia management.
- name: Dantrolene for malignant hyperthermia
  description: >
    Dantrolene sodium is the specific treatment for acute malignant hyperthermia
    episodes. It acts by inhibiting calcium release from the sarcoplasmic
    reticulum via the ryanodine receptor. Dantrolene should be immediately
    available whenever a susceptible patient undergoes anesthesia.
  treatment_term:
    preferred_term: Dantrolene therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: dantrolene
      term:
        id: CHEBI:4317
        label: dantrolene
  evidence:
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Administration of intravenous dantrolene sodium (initial dose of 2.5 mg/kg)
      as early as possible during an MH episode.
    explanation: >-
      GeneReviews identifies early intravenous dantrolene as targeted therapy
      for malignant hyperthermia episodes.
- name: Physical therapy and rehabilitation
  description: >
    Regular physical therapy focusing on maintaining range of motion, preventing
    contractures, and maximizing functional capacity. Exercise programs should
    be tailored to individual ability.
  treatment_term:
    preferred_term: Physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Core elements of treatment include physical therapy, orthopedic interventions, management of respiratory complications, and feeding problems.
    explanation: >-
      This review identifies physical therapy as a core management component for
      core myopathies including central core disease.
- name: Orthopedic management
  description: >
    Surgical and conservative management of musculoskeletal complications
    including scoliosis, hip dislocation, and foot deformities. Bracing
    and assistive devices may be needed.
  treatment_term:
    preferred_term: orthopedic procedure
    term:
      id: MAXO:0000477
      label: orthopedic procedure
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children should be monitored for the development of scoliosis and other
      skeletal deformities.
    explanation: >-
      This supports active orthopedic monitoring during growth.
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Congenital dislocation and dysplasia of the hip require orthopedic treatment.
    explanation: >-
      This directly supports orthopedic management for hip complications.
- name: Respiratory surveillance and support
  description: >-
    Respiratory function should be followed over time, especially in recessive
    or severe disease and when scoliosis or spinal rigidity is present. Serial
    pulmonary function testing and sleep studies can detect subclinical
    nocturnal hypoventilation; respiratory support is managed according to
    respiratory-muscle involvement.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  evidence:
  - reference: PMID:33458581
    reference_title: Core myopathies - a short review.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Respiratory function should be monitored with serial pulmonary function
      tests, and where indicated, sleep studies.
    explanation: >-
      This supports respiratory surveillance for subclinical or progressive
      respiratory involvement.
- name: Genetic counseling
  description: >
    Genetic counseling for affected families should discuss autosomal dominant
    and autosomal recessive inheritance, recurrence risk, variant interpretation,
    central core disease severity spectrum, and implications for family members
    regarding malignant hyperthermia susceptibility.
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:17504518
    reference_title: "Central core disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Mutational analysis of the RYR1 gene may provide genetic confirmation
      of the diagnosis.
    explanation: >
      Supports the role of genetic testing and counseling in CCD diagnosis
      and family management.
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is appropriate to clarify the status of at-risk relatives of an
      individual diagnosed with MHS to identify those who also have an increased
      susceptibility to MH and thus would benefit from avoiding anesthetic agents
      that increase the risk for an MH episode.
    explanation: >-
      GeneReviews supports family counseling and risk clarification for
      malignant hyperthermia susceptibility.
- name: Family cascade testing for malignant hyperthermia risk
  description: >-
    First-degree relatives and other at-risk family members should be offered
    targeted familial RYR1 variant testing when the pathogenic variant is known.
    If the molecular cause is unknown or testing is inconclusive, muscle biopsy
    with contracture testing can clarify MH susceptibility.
  treatment_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  target_phenotypes:
  - preferred_term: Malignant hyperthermia
    term:
      id: HP:0002047
      label: Malignant hyperthermia
  evidence:
  - reference: PMID:20301325
    reference_title: Nonsyndromic Malignant Hyperthermia Susceptibility.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Evaluations include: multigene panel testing (if the MHS-related causative
      variant in the family is known) and muscle biopsy and contracture testing
      (if the MHS-causative pathogenic variant in the family is not known
    explanation: >-
      GeneReviews supports cascade molecular testing or biopsy/contracture
      testing depending on whether the familial MHS variant is known.
references:
- reference: PMID:20301325
  title: Nonsyndromic Malignant Hyperthermia Susceptibility.
  tags:
  - GeneReviews
  findings: []
- reference: PMID:33458581
  title: Core myopathies - a short review.
  findings: []
notes: >
  Central core myopathy was first described by Shy and Magee in 1956 and was the
  first congenital myopathy defined by a specific histological abnormality. The
  molecular basis was established in 1993 when Zhang et al. and Quane et al.
  independently identified RYR1 mutations in CCD families. The disease has
  significant allelic overlap with malignant hyperthermia susceptibility (MHS1),
  and a single mutation may result in either or both phenotypes; isolated
  MH-only susceptibility is treated as an allelic RYR1-related condition rather
  than a subtype of central core myopathy. The clinical
  spectrum of RYR1-related myopathies extends beyond central core disease to
  include multiminicore disease, centronuclear myopathy, and congenital fiber
  type disproportion, reflecting complex genotype-phenotype relationships. In
  the majority of patients, weakness is static or only slowly progressive, with
  a favourable long-term outcome. Prevalence is unknown but the condition is
  probably more common than other congenital myopathies. Cardiomyopathy is not
  modeled as a central core disease phenotype because the reviewed sources state
  that heart disease is not part of the typical core-myopathy spectrum and that
  cardiomyopathies are not a feature of RYR1-associated central core disease.
datasets:

📚

References & Deep Research

References

PMID:20301325

Nonsyndromic Malignant Hyperthermia Susceptibility.

No top-level findings curated for this source.

PMID:33458581

Core myopathies - a short review.

No top-level findings curated for this source.

Deep Research

Falcon ▸

1. Disease Information

Edison Scientific Literature 68 citations 2026-04-25T18:11:57.792110

1. Disease Information

1.1 Overview (what is the disease?)

CCD is an inherited muscle disorder (congenital myopathy) defined by the presence of central cores in muscle biopsy, typically in type I fibers, and associated congenital-myopathy clinical features (hypotonia, delayed motor milestones, proximal weakness). (baba2024anestheticmanagementof pages 1-2)

1.2 Key identifiers and ontology mappings

Authoritative identifiers available from retrieved sources: - MONDO: MONDO:0007294 (user-specified target) (artifact-00) - OMIM disease: 117000 (Central core disease) (lillis2012clinicalutilitygene pages 1-2) - OMIM gene: RYR1 *180901 (lillis2012clinicalutilitygene pages 1-2) - MeSH: D020512 (“Myopathy, Central Core”) (NCT06157268 chunk 3)

Not found in retrieved evidence: explicit Orphanet (ORPHA) numeric identifier and ICD-10/ICD-11 codes.

1.3 Synonyms / alternative names

Central core disease (CCD) (lillis2012clinicalutilitygene pages 1-2)
Central core myopathy (baba2024anestheticmanagementof pages 1-2)
Central core myopathy (CCM) (crisafulli2024casereporta pages 1-2)

1.4 Evidence provenance

Evidence in this report is derived from aggregated disease resources (e.g., gene cards and reviews), cohort studies, clinical trials registries, and case reports; not from EHR-only sources. (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 4-6, NCT02362425 chunk 1)

Item category	Data point	Source (authors/year/journal)	Publication date	URL	Evidence notes
Disease identifier	MONDO:0007294	User-provided target disease metadata	not stated	not available	Included from the task specification; not independently confirmed in retrieved literature.
Disease identifier	OMIM disease: #117000 (Central core disease)	Lillis et al., 2012, European Journal of Human Genetics	2012-10	https://doi.org/10.1038/ejhg.2011.179	Explicit OMIM disease identifier reported in gene card (lillis2012clinicalutilitygene pages 1-2).
Gene identifier	OMIM gene: *RYR1 180901**	Lillis et al., 2012, European Journal of Human Genetics	2012-10	https://doi.org/10.1038/ejhg.2011.179	Explicit OMIM gene identifier for the main causal gene (lillis2012clinicalutilitygene pages 1-2).
Disease identifier	MeSH: D020512 (“Myopathy, Central Core”)	ClinicalTrials.gov record NCT06157268	2024	https://clinicaltrials.gov/study/NCT06157268	Explicit MeSH term/ID listed in trial metadata (NCT06157268 chunk 3).
Synonym / naming	Central core disease (CCD)	Lillis et al., 2012, European Journal of Human Genetics	2012-10	https://doi.org/10.1038/ejhg.2011.179	Gene card uses “Central core disease (CCD) and related phenotypes” (lillis2012clinicalutilitygene pages 1-2).
Synonym / naming	Central core myopathy / CCM	Crisafulli et al., 2024, Frontiers in Physiology	2024-07	https://doi.org/10.3389/fphys.2024.1404657	Case report explicitly uses “Central core myopathy (CCM)” (crisafulli2024casereporta pages 1-2).
Epidemiology	Frequency estimate: 1 in 250,000	Lillis et al., 2012, European Journal of Human Genetics	2012-10	https://doi.org/10.1038/ejhg.2011.179	Regional study in north of England cited as CCD frequency estimate (lillis2012clinicalutilitygene pages 1-2, lillis2012clinicalutilitygene pages 2-3).
Epidemiology	Prevalence estimate: 1–9 per 1,000,000	Crisafulli et al., 2024, Frontiers in Physiology	2024-07	https://doi.org/10.3389/fphys.2024.1404657	Recent case report cites rare-disease prevalence estimate and attributes it to Orphanet (crisafulli2024casereporta pages 1-2).
Epidemiology / ascertainment	CCD represented 53% (92/173) of diagnoses in a 2024 RYR1-RD survey	van de Camp et al., 2024, Journal of Neuromuscular Diseases	2024-08	https://doi.org/10.3233/jnd-240029	Reflects distribution within a surveyed RYR1-related disease cohort, not population prevalence (camp2024individualsandfamilies pages 4-5).
Inheritance	Predominantly autosomal dominant, with less frequent recessive forms	Lillis et al., 2012, European Journal of Human Genetics	2012-10	https://doi.org/10.1038/ejhg.2011.179	Gene card states RYR1-associated CCD is mostly dominant but recessive inheritance also occurs (lillis2012clinicalutilitygene pages 1-2).
Inheritance	AD in 4 families; AR in 2 families; sporadic cases common	Cotta et al., 2022, Genes	2022-04	https://doi.org/10.3390/genes13050760	In 27 Brazilian CCD patients: 11 AD, 3 AR, 13 sporadic; biallelic RYR1 variants in 43% of molecularly analyzed families (cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease pages 9-10).
Inheritance	Autosomal dominant entry in treatment phenotype table; onset neonatal or later infancy	Raga et al., 2024, treatment protocol	2024	not available	Protocol table lists central core disease as AD with early-life onset; useful as current summary but protocol/non-final source (raga2024treatmentsforryr1relateddisorders pages 12-13).
Hallmark finding	Muscle biopsy hallmark: well-defined central/eccentric cores running along longitudinal fiber axis	Lillis et al., 2012, European Journal of Human Genetics	2012-10	https://doi.org/10.1038/ejhg.2011.179	Classic histopathologic criterion for CCD diagnosis (lillis2012clinicalutilitygene pages 1-2).
Hallmark finding	Cores are areas devoid of oxidative reaction with myofibrillar disorganization and scarce mitochondria	Cotta et al., 2022, Genes	2022-04	https://doi.org/10.3390/genes13050760	Histology in cohort supports mitochondrial depletion/oxidative stain loss as core feature (cotta2022centralcoredisease pages 4-6).
Hallmark finding	Clinical pattern: hypotonia and predominantly proximal weakness	Cotta et al., 2022, Genes	2022-04	https://doi.org/10.3390/genes13050760	In cohort, hypotonia common and weakness proximal in 96%; childhood onset in nearly all patients (cotta2022centralcoredisease pages 4-6).
Hallmark finding	Orthopedic features: hip dislocation, scoliosis/kyphoscoliosis, club feet, joint contractures	Cotta et al., 2022, Genes; Raga et al., 2024, protocol	2022-04; 2024	https://doi.org/10.3390/genes13050760	Recurrent musculoskeletal complications across cohort/protocol summaries (cotta2022centralcoredisease pages 4-6, raga2024treatmentsforryr1relateddisorders pages 12-13).
Hallmark finding	EMG often myopathic; CK usually normal or near-normal	Cotta et al., 2022, Genes	2022-04	https://doi.org/10.3390/genes13050760	EMG myopathic in 88%; CK normal/near-normal in 84% of cohort (cotta2022centralcoredisease pages 4-6).
Hallmark finding / imaging	Selective muscle imaging pattern can support RYR1 involvement; e.g., rectus femoris relative sparing vs vasti	Lillis et al., 2012, European Journal of Human Genetics; Cotta et al., 2022, Genes	2012-10; 2022-04	https://doi.org/10.1038/ejhg.2011.179	MRI pattern described in gene card; cohort figure showed severe vastus lateralis fat replacement with relative rectus femoris preservation (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease media ead0977b).
Hallmark association	Increased risk of malignant hyperthermia susceptibility (MHS) with RYR1-related CCD	Lillis et al., 2012, European Journal of Human Genetics; Baba et al., 2024, Cureus	2012-10; 2024-01	https://doi.org/10.1038/ejhg.2011.179	Important disease-defining association for peri-anesthetic management; trigger-free anesthesia recommended (lillis2012clinicalutilitygene pages 4-5, baba2024anestheticmanagementof pages 1-2).

Table: This table compiles core disease-level facts for Central Core Myopathy/Disease, including identifiers, naming, epidemiology, inheritance, and hallmark clinical-pathologic findings. It is designed as a compact evidence-backed reference for knowledge-base population.

2. Etiology

2.1 Disease causal factors

Primary cause: Germline pathogenic variants in RYR1 are the major cause of CCD/central core myopathy. (leao2020dominantorrecessive pages 2-3, cotta2022centralcoredisease pages 7-9)

Rare alternative/phenocopy cause: Recessive CCD due to NEB variants has been reported (gene-card evidence; details not captured in retrieved pages). (lillis2012clinicalutilitygene pages 5-5)

2.2 Risk factors

Genetic risk factors

RYR1 pathogenic variants (dominant or recessive) are causal. Many CCD alleles are missense variants, with clustering in the C-terminal hotspot region, but pathogenic variants also occur outside hotspots—supporting whole-gene sequencing strategies. (leao2020dominantorrecessive pages 1-2, cotta2022centralcoredisease pages 7-9)
MH risk is an important associated risk: RYR1 variants may confer susceptibility to malignant hyperthermia, sometimes independently of overt myopathy severity. (lillis2012clinicalutilitygene pages 4-5, rosenberg2015malignanthyperthermiaa pages 4-5)

Environmental/iatrogenic risk factors

Exposure to malignant hyperthermia triggers (volatile anesthetics and succinylcholine) is a major avoidable risk for life-threatening MH episodes in susceptible individuals. (baba2024anestheticmanagementof pages 1-2, rosenberg2015malignanthyperthermiaa pages 4-5)
Exertion/heat can precipitate episodic symptoms (myalgia, rhabdomyolysis) across the RYR1 spectrum. (crisafulli2024casereporta pages 1-2, o’connor2023ryr1relateddiseasesinternational pages 3-4)

2.3 Protective factors

No specific genetic protective alleles or proven environmental protective factors were identified in the retrieved CCD-focused evidence. Tailored exercise programs may reduce deconditioning and improve fitness while minimizing rhabdomyolysis risk, but are not “protective” in a causal sense. (crisafulli2024casereporta pages 1-2)

2.4 Gene–environment interactions

Best-supported interaction is RYR1 genotype × anesthetic trigger exposure, which can precipitate MH through abnormal RyR1-mediated Ca2+ release and hypermetabolism. (rosenberg2015malignanthyperthermiaa pages 4-5)

3. Phenotypes

3.1 Core phenotype spectrum

Across cohorts and surveys, CCD/RYR1-related disease most commonly features: - Early hypotonia and delayed motor milestones (cotta2022centralcoredisease pages 4-6) - Predominantly proximal weakness (96% in a CCD cohort) with variable distal/axial involvement (cotta2022centralcoredisease pages 4-6) - Orthopedic complications including congenital hip dislocation, clubfeet, scoliosis/kyphoscoliosis, contractures (cotta2022centralcoredisease pages 4-6, raga2024treatmentsforryr1relateddisorders pages 12-13) - Myalgia/cramps, fatigue, heat intolerance, exercise limitations—prominent in patient-reported studies across the RYR1 spectrum (o’connor2023ryr1relateddiseasesinternational pages 3-4, camp2024individualsandfamilies pages 13-15)

3.2 Frequencies, onset, severity, progression

Quantitative cohort data (example single-center CCD cohort, Brazil, n=27): - Childhood onset in almost all patients (cotta2022centralcoredisease pages 4-6) - Hypotonia: 14/23; developmental delay: 15/23 (cotta2022centralcoredisease pages 4-6) - Proximal weakness: 96%; distal weakness 26%; axial weakness 32% (cotta2022centralcoredisease pages 4-6) - Deep tendon reflexes absent 45%, decreased 29% (cotta2022centralcoredisease pages 4-6) - CK normal/near normal in 84% (cotta2022centralcoredisease pages 4-6) - Facial weakness 8/27 overall, but much higher in biallelic vs monoallelic cases (71% vs 6.7%), suggesting facial weakness as a marker of recessive/biallelic disease in that cohort. (cotta2022centralcoredisease pages 7-9)

Patient-reported disease burden (international RYR1-RD survey summarized at 2022 workshop; n=226): - Most common self-reported diagnosis: CCD 53.2% (o’connor2023ryr1relateddiseasesinternational pages 3-4) - Ambulation: 64.2% walk unassisted; 11.9% require assistance; 5.8% require wheelchair assistance (o’connor2023ryr1relateddiseasesinternational pages 3-4) - Disease course perception: 47.1% progressive, 33.9% non-progressive (o’connor2023ryr1relateddiseasesinternational pages 3-4) - Challenges: 88.9% physical, 63.7% emotional, 58% social (o’connor2023ryr1relateddiseasesinternational pages 3-4)

Patient/caregiver perspective study (2024; n=227) similarly found that only 8% reported no impact on well-being and emphasized fatigue/weakness and higher burden in congenital myopathies compared with MHS. (camp2024individualsandfamilies pages 13-15)

3.3 Quality of life impact

Patient-reported evidence shows substantial impact on overall well-being, functional limitations, fatigue and pain, with congenital myopathy phenotypes (including CCD) more affected than MHS-only phenotypes. (camp2024individualsandfamilies pages 13-15)

3.4 Suggested HPO terms

Phenotype (plain language)	Suggested HPO term (name and HP ID if known)	Typical onset/course	Frequency/notes	Key supporting sources (author/year) with URL
Congenital/early hypotonia	Hypotonia (HP:0001252)	Usually neonatal or childhood onset; often non-progressive or slowly progressive, though ~47% of surveyed RYR1-RD patients perceived progression	In a CCD cohort, hypotonia in 14/23 (60.9%); central core myopathy typically presents postnatally with hypotonia (cotta2022centralcoredisease pages 4-6, crisafulli2024casereporta pages 1-2, camp2024individualsandfamilies pages 5-7)	Cotta 2022 — https://doi.org/10.3390/genes13050760; Crisafulli 2024 — https://doi.org/10.3389/fphys.2024.1404657; van de Camp 2024 — https://doi.org/10.3233/jnd-240029
Delayed motor milestones / developmental motor delay	Delayed gross motor development (HP:0002194)	Infancy/early childhood onset; may improve in milder cases but can persist	Developmental delay in 15/23 (65.2%) in CCD cohort; many patient testimonials describe early developmental delay (cotta2022centralcoredisease pages 4-6, camp2024individualsandfamilies pages 5-7)	Cotta 2022 — https://doi.org/10.3390/genes13050760; van de Camp 2024 — https://doi.org/10.3233/jnd-240029
Proximal muscle weakness (hip-girdle predominant)	Proximal muscle weakness (HP:0003701)	Usually childhood onset; often mild/non-progressive in dominant CCD, but variable	Proximal weakness in 96% of CCD cohort; classic CCM description emphasizes pelvic-girdle/axial weakness (cotta2022centralcoredisease pages 4-6, crisafulli2024casereporta pages 1-2)	Cotta 2022 — https://doi.org/10.3390/genes13050760; Crisafulli 2024 — https://doi.org/10.3389/fphys.2024.1404657
Axial muscle weakness	Axial muscle weakness (HP:0003323, HPO ID to verify)	Early onset; variable severity	Axial weakness in 32% of CCD cohort; often accompanies proximal pattern (cotta2022centralcoredisease pages 4-6)	Cotta 2022 — https://doi.org/10.3390/genes13050760
Distal muscle weakness	Distal muscle weakness (HP:0002460)	Less common; childhood onset when present	Distal weakness in 26% of CCD cohort (cotta2022centralcoredisease pages 4-6)	Cotta 2022 — https://doi.org/10.3390/genes13050760
Facial weakness	Facial weakness (HP:0000297)	Childhood onset; may help identify biallelic disease	Facial weakness in 8/27 (29.6%) overall; markedly higher in biallelic vs monoallelic CCD, 71.0% vs 6.7% (cotta2022centralcoredisease pages 7-9, cotta2022centralcoredisease pages 9-10)	Cotta 2022 — https://doi.org/10.3390/genes13050760
Ptosis	Ptosis (HP:0000508)	Uncommon; variable onset	Rare in CCD cohort: 2/28 (7.1%); no ophthalmoplegia reported in that cohort (cotta2022centralcoredisease pages 4-6)	Cotta 2022 — https://doi.org/10.3390/genes13050760
Reduced/absent reflexes	Areflexia (HP:0001284) / Hyporeflexia (HP:0001265)	Chronic; accompanies weakness	Deep tendon reflexes absent in 45% and decreased in 29% of CCD cohort (cotta2022centralcoredisease pages 4-6)	Cotta 2022 — https://doi.org/10.3390/genes13050760
Myalgia / muscle pain	Myalgia (HP:0003326)	Can occur from childhood through adulthood; may worsen with exertion	Common in broader RYR1-RD survey; CCM case literature notes exertional myalgia; O’Connor workshop lists myalgia among prominent symptoms (crisafulli2024casereporta pages 1-2, camp2024individualsandfamilies pages 13-15, o’connor2023ryr1relateddiseasesinternational pages 3-4)	Crisafulli 2024 — https://doi.org/10.3389/fphys.2024.1404657; van de Camp 2024 — https://doi.org/10.3233/jnd-240029; O’Connor 2023 — https://doi.org/10.3233/jnd-221609
Fatigue / easy fatigability	Fatigability (HP:0012378, HPO ID to verify)	Chronic across lifespan; major contributor to quality-of-life burden	Fatigue is a key symptom in RYR1-RD surveys; only 8% reported no impact on well-being; fatigue/pain more pronounced in congenital myopathies including CCD (camp2024individualsandfamilies pages 13-15, camp2024individualsandfamilies pages 1-3)	van de Camp 2024 — https://doi.org/10.3233/jnd-240029
Exercise intolerance	Exercise intolerance (HP:0003546)	Often lifelong; may trigger myalgia/rhabdomyolysis	Survey respondents reported difficulty walking/running and benefit from carefully selected activity; exercise-induced symptoms recognized in CCM (o’connor2023ryr1relateddiseasesinternational pages 3-4, crisafulli2024casereporta pages 1-2)	O’Connor 2023 — https://doi.org/10.3233/jnd-221609; Crisafulli 2024 — https://doi.org/10.3389/fphys.2024.1404657
Rhabdomyolysis risk with exertion	Rhabdomyolysis (HP:0003201)	Episodic; may be triggered by exercise/heat	Recognized complication/risk in CCM; case report highlights concern for exercise-induced rhabdomyolysis and myalgia (crisafulli2024casereporta pages 1-2)	Crisafulli 2024 — https://doi.org/10.3389/fphys.2024.1404657
HyperCKemia / elevated creatine kinase	Elevated circulating creatine kinase concentration (HP:0003236)	Intermittent or mild; not universal	CK is usually normal or near-normal in classic CCD (84% in Cotta cohort), but hyperCKemia is reported in some CCM patients (cotta2022centralcoredisease pages 4-6, crisafulli2024casereporta pages 1-2)	Cotta 2022 — https://doi.org/10.3390/genes13050760; Crisafulli 2024 — https://doi.org/10.3389/fphys.2024.1404657
Scoliosis / kyphoscoliosis	Scoliosis (HP:0002650) / Kyphoscoliosis (HP:0002751)	May emerge in childhood/adolescence; chronic orthopedic complication	Frequently reported across CCD/RYR1-RD summaries and surveys; included among orthopedic complications in workshop and protocol summaries (o’connor2023ryr1relateddiseasesinternational pages 3-4, raga2024treatmentsforryr1relateddisorders pages 12-13)	O’Connor 2023 — https://doi.org/10.3233/jnd-221609; Raga 2024 — not provided in evidence text
Congenital hip dislocation	Congenital hip dislocation (HP:0001385, HPO ID to verify)	Congenital	In CCD cohort, hip dislocation in 5/25 (20%); workshop survey also notes hip dislocation among frequent problems (cotta2022centralcoredisease pages 4-6, o’connor2023ryr1relateddiseasesinternational pages 3-4)	Cotta 2022 — https://doi.org/10.3390/genes13050760; O’Connor 2023 — https://doi.org/10.3233/jnd-221609
Club feet / foot deformity	Talipes equinovarus (HP:0001762) / Foot deformity (HP:0001760)	Congenital or early childhood	Club feet in 4/26 (15.4%) in CCD cohort; foot deformities also listed in phenotype summaries (cotta2022centralcoredisease pages 4-6, raga2024treatmentsforryr1relateddisorders pages 12-13)	Cotta 2022 — https://doi.org/10.3390/genes13050760; Raga 2024 — not provided in evidence text
Joint contractures / stiff joints	Joint contracture (HP:0001371)	Congenital or progressive over time	Stiff joints were frequent in workshop survey; contractures appear in RYR1-RD phenotype tables (o’connor2023ryr1relateddiseasesinternational pages 3-4, raga2024treatmentsforryr1relateddisorders pages 12-13)	O’Connor 2023 — https://doi.org/10.3233/jnd-221609; Raga 2024 — not provided in evidence text
Respiratory involvement / breathing difficulty	Respiratory insufficiency due to muscle weakness (HP:0002747, HPO ID to verify)	Usually neonatal in severe cases or later with more severe disability	Severe neonatal respiratory involvement in 2/17 (11.8%) in CCD cohort; breathing difficulties more frequent in full-time wheelchair users in survey data (cotta2022centralcoredisease pages 4-6, camp2024individualsandfamilies pages 5-7)	Cotta 2022 — https://doi.org/10.3390/genes13050760; van de Camp 2024 — https://doi.org/10.3233/jnd-240029
Bulbar/feeding problems	Dysphagia (HP:0002015) / Feeding difficulties (HP:0011968, HPO ID to verify)	Early onset in more severe cases	Bulbar symptoms in 3/15 (20%) in CCD cohort; feeding difficulties noted in RYR1 phenotype summaries (cotta2022centralcoredisease pages 4-6, raga2024treatmentsforryr1relateddisorders pages 13-15)	Cotta 2022 — https://doi.org/10.3390/genes13050760; Raga 2024 — not provided in evidence text
Heat intolerance / muscle tightness-cramping	Heat intolerance (HP:0002046, HPO ID to verify) / Muscle cramp (HP:0003394)	Episodic; often exertion/heat related	Workshop survey highlighted heat intolerance, muscle tightness/cramping among frequent symptoms (o’connor2023ryr1relateddiseasesinternational pages 3-4)	O’Connor 2023 — https://doi.org/10.3233/jnd-221609
Ambulation impairment / wheelchair dependence	Abnormality of gait (HP:0001288) / Wheelchair dependence (HP:0002495, HPO ID to verify)	Variable progression; severity tracks inheritance and symptom burden	In 2024 survey: 65% walked unassisted, 12% with assistance, 6% required wheelchair assistance, 17% full-time wheelchair; AR/de novo cases had higher full-time wheelchair use (30.5% and 38% vs 5%) (camp2024individualsandfamilies pages 4-5, camp2024individualsandfamilies pages 5-7)	van de Camp 2024 — https://doi.org/10.3233/jnd-240029
Perceived disease progression	Progressive muscle weakness (HP:0003325, HPO ID to verify)	Variable; some stable, some progressive	47% of RYR1-RD respondents considered symptoms progressive and 34% stable; classic dominant CCD often described as mild/non-progressive, so progression is heterogeneous (camp2024individualsandfamilies pages 5-7, o’connor2023ryr1relateddiseasesinternational pages 3-4, cotta2022centralcoredisease pages 9-10)	van de Camp 2024 — https://doi.org/10.3233/jnd-240029; O’Connor 2023 — https://doi.org/10.3233/jnd-221609; Cotta 2022 — https://doi.org/10.3390/genes13050760

Table: This table maps major clinical features reported for central core disease/myopathy to suggested HPO terms, with onset/course and frequency notes drawn from cohort and survey evidence. It is useful for structured phenotype annotation and knowledge-base population.

4. Genetic / Molecular Information

4.1 Causal genes

RYR1 is the principal causal gene for CCD/central core myopathy. (leao2020dominantorrecessive pages 2-3, cotta2022centralcoredisease pages 7-9)
NEB: rare recessive CCD reported (limited details in retrieved evidence). (lillis2012clinicalutilitygene pages 5-5)

4.2 Pathogenic variant classes, hotspots, and example alleles

In RYR1-related CCD cohorts, the variant spectrum is predominantly missense, with additional truncating/intronic variants: - In one Brazilian cohort, 22/23 variants were missense and 1 was frameshift (leao2020dominantorrecessive pages 2-3) - In another CCD cohort, 16/18 variants were missense, 1 nonsense, 1 intronic (cotta2022centralcoredisease pages 7-9)

Hotspots/domain trends: - CCD alleles often cluster in a C-terminal “D3” hotspot region, while MH alleles are commonly in N-terminal/central hotspots, although overlap occurs and variants outside hotspots exist. (leao2020dominantorrecessive pages 1-2, cotta2022centralcoredisease pages 9-10)

Monoallelic vs biallelic inheritance: - Biallelic (recessive/compound heterozygous) disease can represent a substantial fraction of cases in some series (e.g., 6/14 families biallelic in one cohort). (cotta2022centralcoredisease pages 7-9)

4.3 Functional consequences (mechanistic genotype → phenotype)

MH is frequently described as gain-of-function (hypersensitive RyR1 with excessive SR Ca2+ release). (schartner2019abnormalexcitationcontractioncoupling pages 4-6)
CCD is often described as loss-of-function / ECC uncoupling with reduced depolarization-induced Ca2+ release, though some variants may also produce Ca2+ leak phenotypes. (parker2017functionalcharacterizationof pages 1-3)

4.4 Modifier genes / epigenetics

No specific validated modifier genes for CCD were identified in retrieved evidence beyond broader discussions of Ca2+ handling and oxidative stress pathways; the 2023 workshop report emphasizes discovery of modifiers and high-throughput screens for RyR1 and SERCA1 modulators. (o’connor2023ryr1relateddiseasesinternational pages 14-16)

Gene	Role	Inheritance patterns	Variant classes reported (missense/nonsense/frameshift/intronic)	Example variants (protein change)	Hotspot/domain notes	Evidence notes (e.g., % missense; biallelic rates)	Key sources with publication date and URL
RYR1	Encodes the skeletal-muscle ryanodine receptor 1, the principal sarcoplasmic reticulum Ca²⁺ release channel required for excitation-contraction coupling and the major causal gene for central core disease/myopathy	Predominantly autosomal dominant; also autosomal recessive/biallelic; sporadic and de novo cases reported; some alleles linked to malignant hyperthermia susceptibility	Predominantly missense; also nonsense, frameshift, and intronic variants reported	p.Arg4861His, p.Arg4861Cys, p.Arg4914Met, p.Arg4914Thr, p.Ala4846Val, p.Gly4897Asp, p.Gln1613Ter, p.Y4864H	Classic hotspot regions D1 (N-terminal), D2 (central), D3/C-terminal; CCD-associated variants predominate in the C-terminal/transmembrane D3 region, but pathogenic alleles also occur outside hotspots; some pore/selectivity-filter enrichment described in recessive disease	In Brazilian CCD cohort, 22/23 (95.7%) detected variants were missense and 1 was frameshift; 7/20 families had biallelic mutations, corresponding to about 30% possible AR inheritance (Leão 2020). In another CCD cohort, 16/18 (~89%) variants were missense, 1 nonsense, 1 intronic; 6/14 families (43%) had biallelic variants and 8/14 (57%) monoallelic variants (Cotta 2022). Recessive RYR1 series showed hypomorphic/null alleles enriched in more severe and often non-core phenotypes, while missense variants were enriched in MH/CCD hotspots and pore/selectivity filter regions (Amburgey 2013). Functional studies support both gain-of-function/MH-type and loss-of-function/EC-uncoupling CCD-type mechanisms depending on variant (Parker 2017) (leao2020dominantorrecessive pages 2-3, leao2020dominantorrecessive pages 1-2, cotta2022centralcoredisease pages 9-10, cotta2022centralcoredisease pages 7-9, amburgey2013genotypephenotypecorrelationsin pages 1-2, amburgey2013genotypephenotypecorrelationsin pages 10-11, parker2017functionalcharacterizationof pages 1-3)	Leão et al. 2020-12, Acta Myologica, https://doi.org/10.36185/2532-1900-030; Cotta et al. 2022-04, Genes, https://doi.org/10.3390/genes13050760; Lillis et al. 2012-10, Eur J Hum Genet, https://doi.org/10.1038/ejhg.2011.179; Amburgey et al. 2013-08, Orphanet J Rare Dis, https://doi.org/10.1186/1750-1172-8-117; Parker et al. 2017-05, J Neuromuscul Dis, https://doi.org/10.3233/jnd-170210; Cacheux et al. 2015-11, J Neuromuscul Dis, https://doi.org/10.3233/jnd-150073
NEB	Encodes nebulin, a giant sarcomeric thin-filament protein; rarely implicated in recessive core myopathy/central core-like disease rather than classic RYR1-related CCD	Autosomal recessive reported	Not specified in retrieved evidence for CCD-specific cases	Not specified in retrieved evidence	Not specified in retrieved evidence	Mentioned in the CCD gene card as at least one report of recessive central core disease due to nebulin variants; however, variant-level details, frequencies, and domain mapping were not available in the retrieved evidence. This supports NEB as a rare alternative/phenocopy gene rather than the main CCD gene (lillis2012clinicalutilitygene pages 5-5)	Lillis et al. 2012-10, Eur J Hum Genet, https://doi.org/10.1038/ejhg.2011.179

Table: This table summarizes the main genetic and molecular evidence for central core disease/myopathy, emphasizing RYR1 as the principal causal gene, the distribution of inheritance patterns, reported variant classes, representative alleles, and hotspot/domain information. It is useful for quickly mapping genotype architecture and evidence strength across key foundational studies.

5. Environmental Information

5.1 Environmental and lifestyle contributors

CCD is primarily genetic; major clinically actionable environmental exposures relate to anesthetic triggers of MH and to exertional/heat stress that may precipitate myalgia or rhabdomyolysis in some RYR1 phenotypes. (rosenberg2015malignanthyperthermiaa pages 4-5, crisafulli2024casereporta pages 1-2)

5.2 Infectious agents

Not applicable as a primary etiology based on retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Core mechanistic concept: ECC and Ca2+ dysregulation

RyR1 mediates SR Ca2+ release during skeletal muscle ECC. RYR1 variants can cause: - Excess Ca2+ release/leak (MH-type gain-of-function): hypersensitivity to triggers → uncontrolled Ca2+ release → increased contractile activity and hypermetabolism; SERCA is unable to resequester Ca2+ adequately, increasing ATP consumption and heat. (rosenberg2015malignanthyperthermiaa pages 4-5) - Reduced Ca2+ release / ECC uncoupling (CCD-type loss-of-function): reduced depolarization-induced Ca2+ release and impaired contraction. (parker2017functionalcharacterizationof pages 1-3)

6.2 SOICR (store overload-induced Ca2+ release)

A mechanistic study showed that multiple RyR1 mutations associated with MH and CCD reduce the threshold for SOICR, promoting spontaneous SR Ca2+ release and contracture; dantrolene suppresses SOICR in this model system. (chen2017reducedthresholdfor pages 1-3)

6.3 SOCE and Ca2+ entry pathways

Reviews describe involvement of store-operated Ca2+ entry (STIM1–ORAI1) and other Ca2+ entry pathways in MH-susceptible muscle, linking RyR1 dysfunction to sustained Ca2+ dysregulation. (rosenberg2015malignanthyperthermiaa pages 4-5, schartner2019abnormalexcitationcontractioncoupling pages 1-2)

6.4 Mitochondrial depletion and core pathology

Core lesions show reduced oxidative activity and scarce mitochondria in biopsies, consistent with downstream mitochondrial damage/dysfunction. Mechanistic reviews outline feed-forward loops where Ca2+ leak and oxidative stress (including RyR1 post-translational modifications and FKBP12/calstabin dissociation) promote cytosolic Ca2+ overload, proteolysis, mitochondrial dysfunction and cell death. (cotta2022centralcoredisease pages 4-6, campuzanodonoso2026molecularbasesof pages 7-9)

6.5 Suggested ontology terms

GO Biological Process (examples to annotate; IDs to verify): excitation–contraction coupling; sarcoplasmic reticulum calcium ion release; regulation of cytosolic calcium ion concentration; response to oxidative stress; mitochondrial organization.
GO Cellular Component (examples; IDs to verify): sarcoplasmic reticulum membrane; triad; ryanodine receptor complex; mitochondrion.
CL Cell types (examples; IDs to verify): skeletal muscle fiber (type I), skeletal muscle cell/myofiber.

7. Anatomical Structures Affected

7.1 Primary organs/systems

Skeletal muscle system (primary), especially muscles with selective involvement patterns on imaging (e.g., thigh/lower limb muscles) (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease media ead0977b)

7.2 Tissue/cell level

Skeletal muscle fibers, particularly type I fibers with core lesions. (baba2024anestheticmanagementof pages 1-2)

7.3 Subcellular level

Triad/ECC machinery (T-tubule/SR junction including DHPR–RyR1 coupling) and mitochondria (core-associated depletion/dysfunction). (schartner2019abnormalexcitationcontractioncoupling pages 1-2, cotta2022centralcoredisease pages 4-6)

7.4 Localization (imaging-guided)

Selective muscle involvement patterns (e.g., relative rectus femoris sparing compared with vasti) can guide biopsy and support RYR1 involvement. (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease media ead0977b)

8. Temporal Development

8.1 Onset

Typically congenital/neonatal or childhood onset; adult recognition can occur, especially with mild cases and delayed diagnosis. (cotta2022centralcoredisease pages 4-6, o’connor2023ryr1relateddiseasesinternational pages 3-4)

8.2 Progression

Often described as non-progressive or slowly progressive in classic dominant CCD, but patient-reported data show heterogeneity, with ~47% perceiving progression. (o’connor2023ryr1relateddiseasesinternational pages 3-4, camp2024individualsandfamilies pages 5-7)

8.3 Critical periods

Peri-anesthesia exposure to MH-triggering agents represents a critical risk period. (rosenberg2015malignanthyperthermiaa pages 4-5)

9. Inheritance and Population

9.1 Epidemiology

Frequency estimates reported: - Regional CCD frequency estimate: 1 in 250,000 (north of England study cited in gene card). (lillis2012clinicalutilitygene pages 1-2) - Central core myopathy prevalence estimate cited in 2024 case report: 1–9 per 1,000,000. (crisafulli2024casereporta pages 1-2)

Related RYR1/MH population genetics context in gene card: - Carrier frequency for heterozygous RYR1 mutations in Japan estimated as high as 1 in 2,000 (lillis2012clinicalutilitygene pages 2-3) - Allelic MHS trait estimated 1 in 3,000–10,000; clinical MH reaction prevalence 1 in 60,000–100,000 (gene card summary). (lillis2012clinicalutilitygene pages 2-3)

9.2 Inheritance patterns

Predominantly autosomal dominant, with recessive/biallelic cases increasingly recognized. (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 7-9)

Survey-reported inheritance across RYR1-RD (not population-based): autosomal dominant 27.0%, autosomal recessive 26.1%, de novo 9.3%, unknown 32.7%. (o’connor2023ryr1relateddiseasesinternational pages 3-4)

9.3 Demographics

In a 2024 survey cohort, ages ranged 0–85 years, mean 37±21, with 143 females and 84 males. (camp2024individualsandfamilies pages 4-5)

10. Diagnostics

10.1 Clinical tests

CK: usually normal/near-normal in classic CCD cohorts (84%), though may be elevated in broader RYR1 phenotypes. (cotta2022centralcoredisease pages 4-6)
EMG: myopathic pattern common (88% in one cohort). (cotta2022centralcoredisease pages 4-6)

10.2 Imaging

Characteristic MRI pattern can be highly suggestive of RYR1 involvement and can be used to guide biopsy. (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease media ead0977b)

10.3 Biopsy

Core lesions with oxidative enzyme depletion are hallmark findings; biopsy processing includes oxidative stains (SDH/COX/NADH) and routine histology. (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4)

10.4 Genetic testing

Gene card recommends sequencing the entire RYR1 gene; modern real-world practice often uses neuromuscular NGS panels and broad exome panels with ACMG classification and segregation confirmation. (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4)

10.5 Malignant hyperthermia testing

IVCT/CHCT remains a diagnostic standard but is invasive and limited to specialized centers; DNA testing is increasingly used but challenged by variant interpretation and coverage gaps. (rosenberg2015malignanthyperthermiaa pages 6-8)

Modality/test	What it shows in CCD	Implementation details (e.g., biopsy stains, MRI pattern, EMG yield)	Distinguishing value/differential notes	Supporting sources with URL and publication date
Muscle biopsy (light microscopy)	Hallmark central cores: well-defined single or multiple central/eccentric core lesions extending longitudinally in muscle fibers; areas correspond to myofibrillar disorganization	Recommended after specialist clinical assessment; biopsy can be targeted using imaging. In the Brazilian CCD cohort, biopsies were processed from frozen muscle with H&E, modified Gomori trichrome, PAS ± diastase, Oil-red-O, myosin ATPase, acid phosphatase, nonspecific esterase, and oxidative stains. All examined patients showed core lesions/areas devoid of oxidative reaction (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease pages 4-6)	Helps distinguish CCD from other congenital myopathies, but cores/minicores are not fully specific and can also occur in MYH7, ACTA1, DNM2, and NEB-related disease; therefore pathology must be integrated with genotype and imaging (lillis2012clinicalutilitygene pages 3-4)	Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179; Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760 (lillis2012clinicalutilitygene pages 1-2, lillis2012clinicalutilitygene pages 3-4, cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease pages 4-6)
Oxidative/mitochondrial histochemistry	Core regions are devoid of oxidative enzyme activity with scarce mitochondria/mitochondrial depletion	Stains used in real-world workflows include SDH, COX, and NADH; Cotta et al. reported that biopsy areas lacked oxidative reaction and corresponded to myofibrillar disorganization with scarce mitochondria; figure evidence showed round core structures and EM myofibrillar disorganization (cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease media ead0977b)	Useful for distinguishing CCD from nonspecific myopathy and for confirming that the lesion reflects oxidative/mitochondrial depletion rather than inflammatory necrosis; however, similar oxidative abnormalities may be seen in related core myopathies, so correlation with genetics is required	Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760; figure summary from same source (cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease media ead0977b)
Electron microscopy (when performed)	Ultrastructural confirmation of cores and myofibrillar disorganization	Used as adjunct pathology; Cotta figure summary reported biopsy plus electron microscopy demonstrating characteristic round core structures and myofibrillar disorganization (cotta2022centralcoredisease media ead0977b)	Adds specificity when light microscopy is equivocal; helps separate structured cores from multiminicores/other ultrastructural congenital myopathies	Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760 (cotta2022centralcoredisease media ead0977b)
Muscle MRI / CT pattern	Selective pattern of fatty replacement supporting RYR1 involvement; classic relative sparing of rectus femoris compared with vasti	Lillis gene card describes a characteristic MRI pattern: sparing of rectus femoris vs vasti, adductor longus vs adductor magnus, gracilis vs sartorius; in lower leg, greater peroneal involvement than tibialis anterior and soleus more than gastrocnemii. Cotta cohort used T1 axial MRI or CT to guide biopsy; when vastus lateralis showed fatty replacement, rectus femoris was chosen for biopsy. Figure summary showed severe vastus lateralis fat replacement with relative rectus femoris preservation (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease media ead0977b)	Particularly valuable when biopsy is nonspecific; may be more indicative of RYR1 involvement than biopsy in some cases and helps differentiate RYR1-related core myopathy from other congenital myopathies with different selective involvement patterns (lillis2012clinicalutilitygene pages 1-2)	Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179; Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760 (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4, cotta2022centralcoredisease media ead0977b)
Electromyography (EMG)	Usually a myopathic pattern supportive of congenital myopathy	In the Cotta cohort, EMG showed a myopathic pattern or myopathic motor unit potentials in 88% of patients (21/24) (cotta2022centralcoredisease pages 4-6)	Supports myopathy over neuropathy/SMA, but is not disease-specific; useful in differential diagnosis when combined with biopsy and genetics	Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760 (cotta2022centralcoredisease pages 4-6)
Serum creatine kinase (CK)	Often normal or near-normal in CCD; occasionally elevated	In Cotta et al., CK was normal or near-normal in 84% (22/26), with one marked elevation; ancillary labs in clinical workflows also included aldolase (cotta2022centralcoredisease pages 4-6, cotta2022centralcoredisease pages 2-4)	Near-normal CK helps distinguish CCD from many muscular dystrophies with consistently higher CK; however, episodic hyperCKemia/rhabdomyolysis can occur in the broader RYR1 spectrum	Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760 (cotta2022centralcoredisease pages 4-6, cotta2022centralcoredisease pages 2-4)
Genetic testing: single-gene/full-gene RYR1 sequencing	Identifies causal RYR1 variants; can confirm dominant monoallelic or recessive biallelic disease	Lillis recommends sequencing the entire RYR1 gene to resolve diagnosis because hotspot-only approaches can miss variants; definitive diagnosis requires one dominant pathogenic variant or two recessive variants in trans. Sanger sequencing was the standard in 2012, with confirmation of variants on repeat analysis and use of cDNA when needed (lillis2012clinicalutilitygene pages 4-5, lillis2012clinicalutilitygene pages 1-2)	Crucial because pathology can be atypical or overlap with other congenital myopathies; enables family testing, inheritance clarification, MH counseling, and predictive/prenatal testing	Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179 (lillis2012clinicalutilitygene pages 4-5, lillis2012clinicalutilitygene pages 1-2)
Genetic testing: NGS neuromuscular panel	Broad detection of RYR1 and differential congenital myopathy genes	In Cotta et al., first-line testing used a customized 95-gene neuromuscular NGS panel including RYR1, followed by broader exome capture when needed; variant filtering used gnomAD/ExAC/1000 Genomes/ClinVar/HGMD/LOVD and ACMG criteria, with Sanger confirmation and segregation (cotta2022centralcoredisease pages 2-4)	Improves yield because CCD can mimic other congenital myopathies and because pathogenic RYR1 variants can lie outside classic hotspots; also helps rule in/out other genetic differentials	Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760 (cotta2022centralcoredisease pages 2-4)
Genetic testing: exome / broad exome panel	Captures atypical or non-hotspot RYR1 variants and alternative diagnoses	Cotta et al. used TruSight One Expanded (>6700 genes) after panel testing; Lillis anticipated increasing roles for NGS, array CGH, and MLPA for larger deletions/duplications/rearrangements (cotta2022centralcoredisease pages 2-4, lillis2012clinicalutilitygene pages 1-2)	Especially useful when biopsy is nonspecific, phenotype is broad, or panel testing is negative; helps distinguish CCD from other congenital myopathies with overlapping core pathology	Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760; Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179 (cotta2022centralcoredisease pages 2-4, lillis2012clinicalutilitygene pages 1-2)
cDNA analysis / copy-number confirmation	Can reveal variants missed on genomic sequencing and confirm structural calls	Lillis notes some causative variants, often recessive, may not be detectable on genomic sequencing and require cDNA analysis; gross deletions/duplications found by NGS should be confirmed with a second technique such as MLPA/array methods (lillis2012clinicalutilitygene pages 1-2)	Important in unresolved suspected CCD with strong clinicopathologic evidence but negative genomic testing	Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179 (lillis2012clinicalutilitygene pages 1-2)
Malignant hyperthermia susceptibility testing (IVCT/CHCT)	Assesses functional susceptibility to MH in CCD/RYR1-variant carriers	Lillis recommends IVCT in patients or asymptomatic carriers >16 years when MH risk of the variant is undocumented. Rosenberg review notes IVCT is a diagnostic standard under EMHG/NAMHG protocols but requires surgical biopsy and specialized centers, and can yield false positives/negatives (lillis2012clinicalutilitygene pages 4-5, rosenberg2015malignanthyperthermiaa pages 6-8)	Key differential/risk linkage: separates structural congenital myopathy diagnosis from peri-anesthetic pharmacogenetic susceptibility assessment; important because not all RYR1 variants have established MH risk	Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179; Rosenberg et al. Orphanet J Rare Dis (2015-08), https://doi.org/10.1186/s13023-015-0310-1 (lillis2012clinicalutilitygene pages 4-5, rosenberg2015malignanthyperthermiaa pages 6-8)
Perioperative risk-management linkage	Genetic/pathologic diagnosis of CCD triggers MH precautions during anesthesia	Baba et al. describe real-world trigger-free anesthesia in CCD: removal of vaporizers, replacement of circuit and soda lime, prolonged machine flush, total intravenous anesthesia, core temperature monitoring, and immediate availability of unopened dantrolene vials; masseter neuromuscular monitoring was used because recovery lagged behind adductor pollicis (baba2024anestheticmanagementof pages 1-2, baba2024anestheticmanagementof pages 4-5)	Distinguishes CCD from other congenital myopathies by the need for MH-focused perioperative planning; diagnosis has direct management implications even outside neuromuscular clinics	Baba et al. Cureus (2024-01), https://doi.org/10.7759/cureus.52456 (baba2024anestheticmanagementof pages 1-2, baba2024anestheticmanagementof pages 4-5)
Differential diagnosis integration (clinicopathologic + imaging + genetics)	Final diagnosis relies on multimodal correlation rather than one test alone	Lillis recommends testing only after specialist clinical, biopsy, and MRI assessment; Cotta integrates EMG, CK, imaging-guided biopsy, and tiered NGS/exome; workshop report highlights broad availability of NGS and expert pathogenicity panels for trial-readiness and care harmonization (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4, o’connor2023ryr1relateddiseasesinternational pages 1-3)	Helps distinguish CCD from multiminicore disease, centronuclear myopathy, congenital fiber-type disproportion, nemaline myopathy, and even neurogenic disorders such as SMA when individual tests are equivocal	Lillis et al. Eur J Hum Genet (2012-10), https://doi.org/10.1038/ejhg.2011.179; Cotta et al. Genes (2022-04), https://doi.org/10.3390/genes13050760; O’Connor et al. J Neuromuscul Dis (2023-01), https://doi.org/10.3233/jnd-221609 (lillis2012clinicalutilitygene pages 1-2, cotta2022centralcoredisease pages 2-4, o’connor2023ryr1relateddiseasesinternational pages 1-3)

Table: This table summarizes the main diagnostic modalities used for central core disease/myopathy, what each contributes, and how they help distinguish CCD from overlapping congenital myopathies and malignant hyperthermia susceptibility.

11. Outcome / Prognosis

CCD prognosis is variable and dependent on genotype (monoallelic vs biallelic), severity of weakness, respiratory involvement, and orthopedic complications. Survey data show that most individuals remain ambulant, but a meaningful subset requires wheelchair assistance and many perceive progression. (camp2024individualsandfamilies pages 4-5, o’connor2023ryr1relateddiseasesinternational pages 3-4)

Quantitative survival and life expectancy statistics specific to CCD were not found in retrieved evidence.

12. Treatment

12.1 Standard of care and supportive management

Supportive care including physiotherapy/rehabilitation and orthopedic management is standard; no cure is established. (crisafulli2024casereporta pages 1-2, ziemian2025integrativeapproachesto pages 36-37)

12.2 Perioperative management (real-world implementation)

Trigger-free anesthesia and careful neuromuscular monitoring are recommended for CCD patients given MH risk; a 2024 case report provides detailed workstation preparation and monitoring steps and emphasizes immediate dantrolene availability. (baba2024anestheticmanagementof pages 1-2)

12.3 Pharmacologic/interventional evidence and trials

NAC (antioxidant): NIH phase II RCT summarized in workshop report; 33 randomized; NAC 30 mg/kg/day for 6 months; did not improve urine 15-F2t isoprostane or 6MWT. ClinicalTrials.gov record NCT02362425 provides trial metadata (completed; results posted 2019-12-24). (o’connor2023ryr1relateddiseasesinternational pages 13-14, NCT02362425 chunk 1)
Salbutamol/albuterol: small pilot and case evidence suggest improved myometry/MRC/FVC in CCD/MmD cohorts and in individual case(s). (raga2024treatmentsforryr1relateddisorders pages 13-15)
Rycal S48168 (ARM210): phase I trial (NCT04141670) summarized by workshop report: 7 participants, 1 month dosing; well tolerated; fatigue scores decreased and shoulder strength trended higher in high-dose group. (o’connor2023ryr1relateddiseasesinternational pages 13-14, NCT04141670 chunk 2)

12.4 MAXO suggestions

See treatment artifact below for suggested MAXO/CHEBI mappings.

Intervention (drug/therapy)	Mechanism/rationale	Evidence type (trial/case report/preclinical)	Key data (dose, duration, sample size, outcomes)	Safety notes	Related ontology term suggestions (MAXO, CHEBI if relevant)	Key sources with publication date, URL, and identifiers (NCT when available)
Trigger-free anesthesia with immediate dantrolene availability	Prevent malignant hyperthermia (MH) in RYR1-related CCD by avoiding volatile anesthetics/succinylcholine and preparing for acute RyR1-mediated hypermetabolic crisis	Real-world case report; guideline-linked perioperative management	2024 CCD thoracoscopic lung resection case used total intravenous anesthesia; workstation prepared by removing vaporizers, replacing circuit and soda lime, flushing with 10 L/min air for 12 h; unopened dantrolene kept immediately available; uneventful course; masseter neuromuscular monitoring suggested as adjunct because recovery there was slower than adductor pollicis (baba2024anestheticmanagementof pages 1-2, baba2024anestheticmanagementof pages 4-5)	Core safety principle is strict trigger avoidance; prolonged effects of non-depolarizing relaxants may occur; dantrolene should be readily available (baba2024anestheticmanagementof pages 1-2)	MAXO: trigger avoidance during anesthesia; perioperative monitoring; emergency dantrolene administration. CHEBI: dantrolene (CHEBI ID to verify), succinylcholine (CHEBI ID to verify), volatile anesthetic agent (CHEBI ID to verify)	Baba et al., 2024-01, https://doi.org/10.7759/cureus.52456; cites EMHG/OrphanAnesthesia guidance (baba2024anestheticmanagementof pages 1-2, baba2024anestheticmanagementof pages 4-5, baba2024anestheticmanagementof pages 5-5)
N-acetylcysteine (NAC)	Antioxidant therapy to reduce oxidative stress/redox imbalance reported in RYR1-related myopathies	Randomized, double-/triple-masked placebo-controlled clinical trial; translational/preclinical rationale	NCT02362425; completed phase 1/2 trial. Enrollment 63 total in registry; workshop summary states 150 screened, 53 entered natural history, 33 randomized 1:1 to NAC vs placebo. Dose: 30 mg/kg/day orally (max 2700 mg/day) for 6 months. Primary endpoints: urine 15-F2t isoprostane and 6MWT. Result: baseline oxidative stress elevated, but NAC did not correct urine 15-F2t isoprostane and did not significantly improve 6MWT; trial did not meet primary efficacy endpoints (o’connor2023ryr1relateddiseasesinternational pages 13-14, NCT02362425 chunk 1)	Reported as well tolerated in workshop summary; lack of efficacy may reflect insufficient muscle target engagement/metabolic degradation rather than clear toxicity (o’connor2023ryr1relateddiseasesinternational pages 13-14, o’connor2023ryr1relateddiseasesinternational pages 11-13)	MAXO: antioxidant therapy; oral administration. CHEBI: N-acetyl-L-cysteine (CHEBI ID to verify)	ClinicalTrials.gov NCT02362425, first results posted 2019-12-24, https://clinicaltrials.gov/study/NCT02362425; workshop synthesis O'Connor et al., 2023-01, https://doi.org/10.3233/jnd-221609 (NCT02362425 chunk 1, o’connor2023ryr1relateddiseasesinternational pages 11-13, o’connor2023ryr1relateddiseasesinternational pages 13-14)
Salbutamol	Beta-agonist used to improve muscle strength and pulmonary function in congenital/core myopathies	Small pilot clinical study; protocol/review summary	In children with CCD/MmD (total n=13; 8 CCD, 5 MmD), oral salbutamol 2 mg four times daily, assessed at 3 and 6 months; reported significant increases in myometry, MRC scores, and FVC between baseline and 6 months; some measures improved by 3 months (raga2024treatmentsforryr1relateddisorders pages 13-15)	Described as well tolerated in pilot summary (raga2024treatmentsforryr1relateddisorders pages 4-5)	MAXO: beta-adrenergic agonist therapy; pulmonary function support. CHEBI: salbutamol/albuterol (CHEBI ID to verify)	Raga et al. protocol summary, 2024, URL not available in retrieved record; workshop notes on COMPIS/salbutamol development in O'Connor et al., 2023-01, https://doi.org/10.3233/jnd-221609 (raga2024treatmentsforryr1relateddisorders pages 13-15, raga2024treatmentsforryr1relateddisorders pages 4-5)
Albuterol plus aerobic exercise	Beta-agonist plus conditioning/rehab to improve strength, respiratory function, and daily function	Case report; supportive clinical evidence	Case report in CCD used albuterol 2 mg daily for 1 year plus aerobic exercise 20 min three times/week; reported “striking increase in strength” at 6 months with further gains at 1 year, including fine motor development, activity, and speech (raga2024treatmentsforryr1relateddisorders pages 13-15)	No major adverse effects reported in summarized case; one older report noted mild contracture progression in a complex case (not central to 2023-2024 focus) (raga2024treatmentsforryr1relateddisorders pages 13-15)	MAXO: beta-agonist therapy; aerobic exercise therapy; physical therapy. CHEBI: albuterol/salbutamol (CHEBI ID to verify)	Raga et al. protocol summary, 2024, URL not available in retrieved record; supportive recent exercise-tailoring case in Front Physiol 2024 below (raga2024treatmentsforryr1relateddisorders pages 13-15)
Tailored mixed aerobic/resistance training with CK/Borg monitoring	Personalized rehabilitation to improve fitness while reducing risk of exertional rhabdomyolysis/myalgia in central core myopathy	2024 case report	17-year-old CCM patient underwent preliminary tolerance testing with three 25-min sessions (aerobic, resistance, mixed) at Borg CR-10 intensity level 6; CK checked 36 h later. Training phase: 3 months, 3 sessions/week, mixed aerobic/resistance plus nutrition plan. Outcomes: anaerobic threshold +6.9%, normalized VO2max +15%, muscle mass +1.1 kg, fat mass −1.1 kg; no pain, rhabdomyolysis, or CK increase versus baseline (crisafulli2024casereporta pages 1-2)	Explicitly designed to mitigate exercise-induced rhabdomyolysis risk; authors propose CK/Borg-based dosing as safety tool (crisafulli2024casereporta pages 1-2)	MAXO: physical therapy; resistance exercise; aerobic exercise; nutritional management; laboratory monitoring. CHEBI: creatine kinase as biomarker (CHEBI/LOINC ID to verify)	Crisafulli et al., 2024-07, https://doi.org/10.3389/fphys.2024.1404657 (crisafulli2024casereporta pages 1-2)
Rycal S48168 / ARM210	RyR1 channel stabilizer; binds/stabilizes closed state to reduce pathological SR Ca2+ leak	Phase I open-label dose-escalation trial; ex vivo and structure-guided translational development	NCT04141670; one-month dosing. Workshop summary: 7 participants received 120 mg/day (n=3) or 200 mg/day (n=4). Primary endpoint safety/tolerability. Results: well tolerated; 3 grade ≥2 adverse events deemed unrelated; no serious AEs; dose-dependent PK; fatigue scores decreased and shoulder abduction strength trended higher in high-dose group, though efficacy signals were mixed (o’connor2023ryr1relateddiseasesinternational pages 13-14). Structural work identified ARM210/S48168 binding in Repeat12 domain and cooperative binding with ATP to stabilize closed RyR1 (o’connor2023ryr1relateddiseasesinternational pages 8-10)	Favorable short-term safety/tolerability profile in phase I; efficacy preliminary only (o’connor2023ryr1relateddiseasesinternational pages 14-16, o’connor2023ryr1relateddiseasesinternational pages 13-14)	MAXO: RyR1 stabilizer therapy; clinical trial participation. CHEBI: S48168/ARM210 (CHEBI ID to verify)	ClinicalTrials.gov NCT04141670, https://clinicaltrials.gov/study/NCT04141670; O'Connor et al., 2023-01, https://doi.org/10.3233/jnd-221609; cited EClinicalMedicine 2024 publication in record (NCT04141670 chunk 2, o’connor2023ryr1relateddiseasesinternational pages 14-16, o’connor2023ryr1relateddiseasesinternational pages 13-14)
Future gene editing: prime editing of RYR1	Correct pathogenic RYR1 variants at nucleotide level; precision therapy concept for mutation-defined disease	In vitro human myoblast proof-of-concept; workshop translational update	Godbout et al. reported 59% correction of recessive T4709M RYR1 mutation in human myoblasts via RNA delivery of prime editing components (godbout2023successfulcorrectionby pages 1-3). Workshop report notes prime editing strategy for recurrent T4706M/T4709M with planned/considered delivery approaches including dual AAV, extracellular vesicles, and lipid nanoparticles, and suggests platform utility beyond one variant (o’connor2023ryr1relateddiseasesinternational pages 11-13, o’connor2023ryr1relateddiseasesinternational pages 10-11)	Major current limitation is delivery; mouse primary cells showed lower transfection/editing efficiency than HEK293T systems (o’connor2023ryr1relateddiseasesinternational pages 10-11)	MAXO: genome editing therapy; gene correction therapy. CHEBI: none established/NA	Godbout et al., 2023-12, https://doi.org/10.3390/cells13010031; O'Connor et al., 2023-01, https://doi.org/10.3233/jnd-221609 (o’connor2023ryr1relateddiseasesinternational pages 11-13, o’connor2023ryr1relateddiseasesinternational pages 10-11, godbout2023successfulcorrectionby pages 1-3)
Preclinical/experimental modifiers: Rycals broadly, AICAR, pyridostigmine, NAC in models	Aim to reduce Ca2+ leak, improve endurance/fatigue, or reduce oxidative stress	Preclinical studies and protocol summaries	Rycals: stabilize RyR channels and reduce Ca2+ leak (raga2024treatmentsforryr1relateddisorders pages 4-5). AICAR: AMPK activation may improve endurance without exercise (raga2024treatmentsforryr1relateddisorders pages 4-5). Pyridostigmine in mouse models showed modest improvement in grip fatigue and treadmill endurance (raga2024treatmentsforryr1relateddisorders pages 13-15). NAC in zebrafish, mice, and human myotubes reduced oxidative stress and improved survival/muscle function preclinically despite negative human trial (raga2024treatmentsforryr1relateddisorders pages 4-5)	Mostly preclinical or early-stage; not established standard of care for CCD (raga2024treatmentsforryr1relateddisorders pages 4-5, raga2024treatmentsforryr1relateddisorders pages 13-15)	MAXO: experimental small-molecule therapy; AMPK activator therapy; cholinesterase inhibitor therapy. CHEBI: AICAR (CHEBI ID to verify), pyridostigmine (CHEBI ID to verify), N-acetylcysteine (CHEBI ID to verify)	Raga et al. protocol summary, 2024, URL not available in retrieved record; O'Connor et al., 2023-01, https://doi.org/10.3233/jnd-221609 (raga2024treatmentsforryr1relateddisorders pages 4-5, raga2024treatmentsforryr1relateddisorders pages 13-15)
Clinical care guidelines and trial-readiness infrastructure	Standardized supportive management and harmonized outcomes/testing to enable safer care and future trials	Workshop/research-network implementation update	Workshop report highlighted comprehensive Clinical Care Guidelines translated into eight languages (www.ryr1.org/ccg), expansion of natural history studies, standardized outcome measures, and patient registries/databases to improve trial readiness and real-world care delivery (o’connor2023ryr1relateddiseasesinternational pages 1-3, o’connor2023ryr1relateddiseasesinternational pages 14-16)	Not a therapy itself, but important systems-level intervention for quality/safety in rare disease care	MAXO: clinical guideline-based care; multidisciplinary care; natural history study participation	O'Connor et al., 2023-01, https://doi.org/10.3233/jnd-221609 (o’connor2023ryr1relateddiseasesinternational pages 14-16, o’connor2023ryr1relateddiseasesinternational pages 1-3)

Table: This table summarizes current and emerging treatments, supportive management, and trial activity relevant to central core disease/myopathy, emphasizing 2023-2024 developments and real-world implementation details. It is useful for linking interventions to mechanism, evidence strength, safety, and ontology annotations.

13. Prevention

The most evidence-supported preventive strategy is primary prevention of MH crises by avoiding triggering anesthetics in individuals with CCD/RYR1 variants and ensuring availability of dantrolene and appropriate perioperative protocols. (baba2024anestheticmanagementof pages 1-2, rosenberg2015malignanthyperthermiaa pages 4-5)

Genetic counseling and cascade testing in families can prevent unrecognized MH risk during anesthesia. (lillis2012clinicalutilitygene pages 4-5)

14. Other Species / Natural Disease

Direct naturally occurring CCD analogs in companion animals were not retrieved for CCD specifically; however, malignant hyperthermia occurs in multiple species (including pigs), and porcine RyR1 mutation R615C is referenced mechanistically for SOICR enhancement. (chen2017reducedthresholdfor pages 1-3)

15. Model Organisms

Model systems used for RYR1/CCD mechanism and therapy development include: - Mouse models: RYR1 knock-in MH models (e.g., R2509C) used for therapy testing; inducible muscle-specific RYR1 knockout mice; models for severe recessive RYR1 myopathy. (o’connor2023ryr1relateddiseasesinternational pages 8-10, o’connor2023ryr1relateddiseasesinternational pages 10-11) - Zebrafish and C. elegans: used for large-scale drug screens and modifier discovery. (o’connor2023ryr1relateddiseasesinternational pages 10-11) - Cellular/in vitro systems: HEK293-based RyR1 assays and reconstituted ECC platform; primary human myoblasts/myotubes derived from patient biopsies used for Ca2+ release assays and screening. (o’connor2023ryr1relateddiseasesinternational pages 8-10, cacheux2015functionalcharacterizationof pages 1-3) - Human myoblast gene editing: prime editing correction of RYR1 T4709M in human myoblasts (59% correction). (godbout2023successfulcorrectionby pages 1-3)

Figure evidence (imaging + biopsy)

A cohort figure demonstrates a typical selective muscle imaging pattern and biopsy core findings (fat replacement in vastus lateralis with relative rectus femoris preservation; biopsy/EM images of cores). (cotta2022centralcoredisease media ead0977b)

Recent developments and expert analysis (2023–2024 emphasis)

1) Patient-centered disease burden and trial readiness: 2023 workshop and 2024 patient/caregiver studies emphasize fatigue, psychosocial impact, and willingness to participate in trials, supporting patient-driven registry infrastructure and outcome-measure development. (o’connor2023ryr1relateddiseasesinternational pages 3-4, camp2024individualsandfamilies pages 13-15, o’connor2023ryr1relateddiseasesinternational pages 14-16)

2) Therapeutic pipeline maturation: completion of early-phase trials (NAC; ARM210/S48168) and design of ongoing trials (e.g., COMPIS salbutamol trial) reflect increasing interventional maturity, with emphasis on standardized functional endpoints (MFM-32, 6MWT, FVC). (o’connor2023ryr1relateddiseasesinternational pages 13-14, o’connor2023ryr1relateddiseasesinternational pages 11-13)

3) Mechanism-driven therapies: mechanistic work on Ca2+ leak/SOICR and channel-stabilizing compounds underpins Rycal development and supports exploration of additional RyR1 modulators; dantrolene remains a mechanistically grounded acute therapy for MH and suppresses SOICR in cellular models. (chen2017reducedthresholdfor pages 1-3, o’connor2023ryr1relateddiseasesinternational pages 13-14)

4) Gene correction proof-of-concept: prime editing correction in human myoblasts (2023) demonstrates feasibility of precise correction for RYR1 point mutations, with delivery as a major remaining barrier. (godbout2023successfulcorrectionby pages 1-3, o’connor2023ryr1relateddiseasesinternational pages 10-11)

Limitations of retrieved evidence

Explicit Orphanet (ORPHA) and ICD-10/ICD-11 codes were not identified in retrieved texts.
CCD-specific mortality/life expectancy data and robust population incidence were not retrieved.
Some ontology IDs (HPO/GO/CL/CHEBI/MAXO) are suggested where standard, but several require verification against the current ontology releases.

References

(lillis2012clinicalutilitygene pages 1-2): Suzanne Lillis, Stephen Abbs, Clemens R Mueller, Francesco Muntoni, and Heinz Jungbluth. Clinical utility gene card for: central core disease. European Journal of Human Genetics, 20:-, Oct 2012. URL: https://doi.org/10.1038/ejhg.2011.179, doi:10.1038/ejhg.2011.179. This article has 10 citations and is from a domain leading peer-reviewed journal.
(cotta2022centralcoredisease pages 4-6): Ana Cotta, Lucas Santos Souza, Elmano Carvalho, Leticia Nogueira Feitosa, Antonio Cunha, Monica Machado Navarro, Jaquelin Valicek, Miriam Melo Menezes, Simone Vilela Nunes Neves, Rafael Xavier-Neto, Antonio Pedro Vargas, Reinaldo Issao Takata, Julia Filardi Paim, and Mariz Vainzof. Central core disease: facial weakness differentiating biallelic from monoallelic forms. Genes, 13:760, Apr 2022. URL: https://doi.org/10.3390/genes13050760, doi:10.3390/genes13050760. This article has 6 citations.
(campuzanodonoso2026molecularbasesof pages 7-9): Martín Campuzano-Donoso, Claudia Reytor-González, Melannie Toral-Noristz, Yamilia González, and Daniel Simancas-Racines. Molecular bases of myopathies and their impact on clinical practice: advances and future perspectives. International Journal of Molecular Sciences, 27:1392, Jan 2026. URL: https://doi.org/10.3390/ijms27031392, doi:10.3390/ijms27031392. This article has 1 citations.
(o’connor2023ryr1relateddiseasesinternational pages 3-4): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(baba2024anestheticmanagementof pages 1-2): Hiroko Baba, Ryo Wakabayashi, Hiroki Ichiyanagi, Aki Suzuki, and Nobukazu Sato. Anesthetic management of a patient with central core disease undergoing thoracoscopic lung resection: the importance of neuromuscular monitoring at the masseter muscle. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52456, doi:10.7759/cureus.52456. This article has 1 citations.
(NCT06157268 chunk 3): The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.. Radboud University Medical Center. 2024. ClinicalTrials.gov Identifier: NCT06157268
(crisafulli2024casereporta pages 1-2): Oscar Crisafulli, Jessica Lacetera, Giorgio Bottoni, Angela Berardinelli, Luca Grattarola, Martina Veltroni, Stefano Acquadro, Massimo Negro, Emanuela Lavaselli, and Giuseppe D’Antona. Case report: a creatine kinase-borg scale values-based approach to tailor physical training in a central core myopathy patient. Frontiers in Physiology, Jul 2024. URL: https://doi.org/10.3389/fphys.2024.1404657, doi:10.3389/fphys.2024.1404657. This article has 7 citations.
(NCT02362425 chunk 1): Antioxidant Therapy in RYR1-Related Congenital Myopathy. National Institute of Nursing Research (NINR). 2015. ClinicalTrials.gov Identifier: NCT02362425
(lillis2012clinicalutilitygene pages 2-3): Suzanne Lillis, Stephen Abbs, Clemens R Mueller, Francesco Muntoni, and Heinz Jungbluth. Clinical utility gene card for: central core disease. European Journal of Human Genetics, 20:-, Oct 2012. URL: https://doi.org/10.1038/ejhg.2011.179, doi:10.1038/ejhg.2011.179. This article has 10 citations and is from a domain leading peer-reviewed journal.
(camp2024individualsandfamilies pages 4-5): Sanne A.J.H. van de Camp, Lizan Stinissen, Andrew Huseth, Brentney Simon, Jennifer Ryan, Anna Sarkozy, Filip Van Petegem, Michael F. Goldberg, Heinz Jungbluth, Johann Böhm, Wija Oortwijn, Robert T. Dirksen, and Nicol C. Voermans. Individuals and families affected by ryr1-related diseases: the patient/caregiver perspective. Journal of Neuromuscular Diseases, 11:1067-1083, Aug 2024. URL: https://doi.org/10.3233/jnd-240029, doi:10.3233/jnd-240029. This article has 2 citations and is from a peer-reviewed journal.
(cotta2022centralcoredisease pages 2-4): Ana Cotta, Lucas Santos Souza, Elmano Carvalho, Leticia Nogueira Feitosa, Antonio Cunha, Monica Machado Navarro, Jaquelin Valicek, Miriam Melo Menezes, Simone Vilela Nunes Neves, Rafael Xavier-Neto, Antonio Pedro Vargas, Reinaldo Issao Takata, Julia Filardi Paim, and Mariz Vainzof. Central core disease: facial weakness differentiating biallelic from monoallelic forms. Genes, 13:760, Apr 2022. URL: https://doi.org/10.3390/genes13050760, doi:10.3390/genes13050760. This article has 6 citations.
(cotta2022centralcoredisease pages 9-10): Ana Cotta, Lucas Santos Souza, Elmano Carvalho, Leticia Nogueira Feitosa, Antonio Cunha, Monica Machado Navarro, Jaquelin Valicek, Miriam Melo Menezes, Simone Vilela Nunes Neves, Rafael Xavier-Neto, Antonio Pedro Vargas, Reinaldo Issao Takata, Julia Filardi Paim, and Mariz Vainzof. Central core disease: facial weakness differentiating biallelic from monoallelic forms. Genes, 13:760, Apr 2022. URL: https://doi.org/10.3390/genes13050760, doi:10.3390/genes13050760. This article has 6 citations.
(raga2024treatmentsforryr1relateddisorders pages 12-13): S Raga, N Voermans, I Perez-Neri, and J Dowling. Treatmentsfor ryr1-related disorders (protocol). Unknown journal, 2024.
(cotta2022centralcoredisease media ead0977b): Ana Cotta, Lucas Santos Souza, Elmano Carvalho, Leticia Nogueira Feitosa, Antonio Cunha, Monica Machado Navarro, Jaquelin Valicek, Miriam Melo Menezes, Simone Vilela Nunes Neves, Rafael Xavier-Neto, Antonio Pedro Vargas, Reinaldo Issao Takata, Julia Filardi Paim, and Mariz Vainzof. Central core disease: facial weakness differentiating biallelic from monoallelic forms. Genes, 13:760, Apr 2022. URL: https://doi.org/10.3390/genes13050760, doi:10.3390/genes13050760. This article has 6 citations.
(lillis2012clinicalutilitygene pages 4-5): Suzanne Lillis, Stephen Abbs, Clemens R Mueller, Francesco Muntoni, and Heinz Jungbluth. Clinical utility gene card for: central core disease. European Journal of Human Genetics, 20:-, Oct 2012. URL: https://doi.org/10.1038/ejhg.2011.179, doi:10.1038/ejhg.2011.179. This article has 10 citations and is from a domain leading peer-reviewed journal.
(leao2020dominantorrecessive pages 2-3): Leonardo Galleni Leão, Lucas Santos Souza, L. Nogueira, R. Pavanello, J. Gurgel-Giannetti, U. Reed, A. Oliveira, T. Cuperman, A. Cotta, Julia FPaim, M. Zatz, and M. Vainzof. Dominant or recessive mutations in the ryr1 gene causing central core myopathy in brazilian patients. Acta Myologica, 39:274-282, Dec 2020. URL: https://doi.org/10.36185/2532-1900-030, doi:10.36185/2532-1900-030. This article has 5 citations and is from a peer-reviewed journal.
(cotta2022centralcoredisease pages 7-9): Ana Cotta, Lucas Santos Souza, Elmano Carvalho, Leticia Nogueira Feitosa, Antonio Cunha, Monica Machado Navarro, Jaquelin Valicek, Miriam Melo Menezes, Simone Vilela Nunes Neves, Rafael Xavier-Neto, Antonio Pedro Vargas, Reinaldo Issao Takata, Julia Filardi Paim, and Mariz Vainzof. Central core disease: facial weakness differentiating biallelic from monoallelic forms. Genes, 13:760, Apr 2022. URL: https://doi.org/10.3390/genes13050760, doi:10.3390/genes13050760. This article has 6 citations.
(lillis2012clinicalutilitygene pages 5-5): Suzanne Lillis, Stephen Abbs, Clemens R Mueller, Francesco Muntoni, and Heinz Jungbluth. Clinical utility gene card for: central core disease. European Journal of Human Genetics, 20:-, Oct 2012. URL: https://doi.org/10.1038/ejhg.2011.179, doi:10.1038/ejhg.2011.179. This article has 10 citations and is from a domain leading peer-reviewed journal.
(leao2020dominantorrecessive pages 1-2): Leonardo Galleni Leão, Lucas Santos Souza, L. Nogueira, R. Pavanello, J. Gurgel-Giannetti, U. Reed, A. Oliveira, T. Cuperman, A. Cotta, Julia FPaim, M. Zatz, and M. Vainzof. Dominant or recessive mutations in the ryr1 gene causing central core myopathy in brazilian patients. Acta Myologica, 39:274-282, Dec 2020. URL: https://doi.org/10.36185/2532-1900-030, doi:10.36185/2532-1900-030. This article has 5 citations and is from a peer-reviewed journal.
(rosenberg2015malignanthyperthermiaa pages 4-5): Henry Rosenberg, Neil Pollock, Anja Schiemann, Terasa Bulger, and Kathryn Stowell. Malignant hyperthermia: a review. Orphanet Journal of Rare Diseases, Aug 2015. URL: https://doi.org/10.1186/s13023-015-0310-1, doi:10.1186/s13023-015-0310-1. This article has 788 citations and is from a peer-reviewed journal.
(camp2024individualsandfamilies pages 13-15): Sanne A.J.H. van de Camp, Lizan Stinissen, Andrew Huseth, Brentney Simon, Jennifer Ryan, Anna Sarkozy, Filip Van Petegem, Michael F. Goldberg, Heinz Jungbluth, Johann Böhm, Wija Oortwijn, Robert T. Dirksen, and Nicol C. Voermans. Individuals and families affected by ryr1-related diseases: the patient/caregiver perspective. Journal of Neuromuscular Diseases, 11:1067-1083, Aug 2024. URL: https://doi.org/10.3233/jnd-240029, doi:10.3233/jnd-240029. This article has 2 citations and is from a peer-reviewed journal.
(camp2024individualsandfamilies pages 5-7): Sanne A.J.H. van de Camp, Lizan Stinissen, Andrew Huseth, Brentney Simon, Jennifer Ryan, Anna Sarkozy, Filip Van Petegem, Michael F. Goldberg, Heinz Jungbluth, Johann Böhm, Wija Oortwijn, Robert T. Dirksen, and Nicol C. Voermans. Individuals and families affected by ryr1-related diseases: the patient/caregiver perspective. Journal of Neuromuscular Diseases, 11:1067-1083, Aug 2024. URL: https://doi.org/10.3233/jnd-240029, doi:10.3233/jnd-240029. This article has 2 citations and is from a peer-reviewed journal.
(camp2024individualsandfamilies pages 1-3): Sanne A.J.H. van de Camp, Lizan Stinissen, Andrew Huseth, Brentney Simon, Jennifer Ryan, Anna Sarkozy, Filip Van Petegem, Michael F. Goldberg, Heinz Jungbluth, Johann Böhm, Wija Oortwijn, Robert T. Dirksen, and Nicol C. Voermans. Individuals and families affected by ryr1-related diseases: the patient/caregiver perspective. Journal of Neuromuscular Diseases, 11:1067-1083, Aug 2024. URL: https://doi.org/10.3233/jnd-240029, doi:10.3233/jnd-240029. This article has 2 citations and is from a peer-reviewed journal.
(raga2024treatmentsforryr1relateddisorders pages 13-15): S Raga, N Voermans, I Perez-Neri, and J Dowling. Treatmentsfor ryr1-related disorders (protocol). Unknown journal, 2024.
(schartner2019abnormalexcitationcontractioncoupling pages 4-6): Vanessa Schartner, Jocelyn Laporte, and Johann Böhm. Abnormal excitation-contraction coupling and calcium homeostasis in myopathies and cardiomyopathies. Journal of Neuromuscular Diseases, 6:289-305, Sep 2019. URL: https://doi.org/10.3233/jnd-180314, doi:10.3233/jnd-180314. This article has 24 citations and is from a peer-reviewed journal.
(parker2017functionalcharacterizationof pages 1-3): Remai Parker, Anja H. Schiemann, Elaine Langton, Terasa Bulger, Neil Pollock, Andrew Bjorksten, Robyn Gillies, David Hutchinson, Richard Roxburgh, and Kathryn M. Stowell. Functional characterization of c-terminal ryanodine receptor 1 variants associated with central core disease or malignant hyperthermia. Journal of Neuromuscular Diseases, 4:147-158, May 2017. URL: https://doi.org/10.3233/jnd-170210, doi:10.3233/jnd-170210. This article has 11 citations and is from a peer-reviewed journal.
(o’connor2023ryr1relateddiseasesinternational pages 14-16): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(amburgey2013genotypephenotypecorrelationsin pages 1-2): Kimberly Amburgey, Angela Bailey, Jean H Hwang, Mark A Tarnopolsky, Carsten G Bonnemann, Livija Medne, Katherine D Mathews, James Collins, Jasper R Daube, Gregory P Wellman, Brian Callaghan, Nigel F Clarke, and James J Dowling. Genotype-phenotype correlations in recessive ryr1-related myopathies. Orphanet Journal of Rare Diseases, 8:117-117, Aug 2013. URL: https://doi.org/10.1186/1750-1172-8-117, doi:10.1186/1750-1172-8-117. This article has 137 citations and is from a peer-reviewed journal.
(amburgey2013genotypephenotypecorrelationsin pages 10-11): Kimberly Amburgey, Angela Bailey, Jean H Hwang, Mark A Tarnopolsky, Carsten G Bonnemann, Livija Medne, Katherine D Mathews, James Collins, Jasper R Daube, Gregory P Wellman, Brian Callaghan, Nigel F Clarke, and James J Dowling. Genotype-phenotype correlations in recessive ryr1-related myopathies. Orphanet Journal of Rare Diseases, 8:117-117, Aug 2013. URL: https://doi.org/10.1186/1750-1172-8-117, doi:10.1186/1750-1172-8-117. This article has 137 citations and is from a peer-reviewed journal.
(chen2017reducedthresholdfor pages 1-3): Wenqian Chen, Andrea Koop, Yingjie Liu, Wenting Guo, Jinhong Wei, Ruiwu Wang, David H. MacLennan, Robert T. Dirksen, and Sui Rong Wayne Chen. Reduced threshold for store overload-induced ca2+ release is a common defect of ryr1 mutations associated with malignant hyperthermia and central core disease. The Biochemical journal, 474 16:2749-2761, Aug 2017. URL: https://doi.org/10.1042/bcj20170282, doi:10.1042/bcj20170282. This article has 36 citations.
(schartner2019abnormalexcitationcontractioncoupling pages 1-2): Vanessa Schartner, Jocelyn Laporte, and Johann Böhm. Abnormal excitation-contraction coupling and calcium homeostasis in myopathies and cardiomyopathies. Journal of Neuromuscular Diseases, 6:289-305, Sep 2019. URL: https://doi.org/10.3233/jnd-180314, doi:10.3233/jnd-180314. This article has 24 citations and is from a peer-reviewed journal.
(rosenberg2015malignanthyperthermiaa pages 6-8): Henry Rosenberg, Neil Pollock, Anja Schiemann, Terasa Bulger, and Kathryn Stowell. Malignant hyperthermia: a review. Orphanet Journal of Rare Diseases, Aug 2015. URL: https://doi.org/10.1186/s13023-015-0310-1, doi:10.1186/s13023-015-0310-1. This article has 788 citations and is from a peer-reviewed journal.
(lillis2012clinicalutilitygene pages 3-4): Suzanne Lillis, Stephen Abbs, Clemens R Mueller, Francesco Muntoni, and Heinz Jungbluth. Clinical utility gene card for: central core disease. European Journal of Human Genetics, 20:-, Oct 2012. URL: https://doi.org/10.1038/ejhg.2011.179, doi:10.1038/ejhg.2011.179. This article has 10 citations and is from a domain leading peer-reviewed journal.
(baba2024anestheticmanagementof pages 4-5): Hiroko Baba, Ryo Wakabayashi, Hiroki Ichiyanagi, Aki Suzuki, and Nobukazu Sato. Anesthetic management of a patient with central core disease undergoing thoracoscopic lung resection: the importance of neuromuscular monitoring at the masseter muscle. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52456, doi:10.7759/cureus.52456. This article has 1 citations.
(o’connor2023ryr1relateddiseasesinternational pages 1-3): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(ziemian2025integrativeapproachesto pages 36-37): Maja Ziemian, Joanna Szmydtka, Wojciech Snoch, Sandra Milner, Szymon Wojciechowski, Aleksandra Dłuszczakowska, Jakub W. Chojnowski, Zofia Pallach, Katarzyna Żamojda, Grzegorz Węgrzyn, and Estera Rintz. Integrative approaches to myopathies and muscular dystrophies: molecular mechanisms, diagnostics, and future therapies. International Journal of Molecular Sciences, 26:7972, Aug 2025. URL: https://doi.org/10.3390/ijms26167972, doi:10.3390/ijms26167972. This article has 3 citations.
(o’connor2023ryr1relateddiseasesinternational pages 13-14): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(NCT04141670 chunk 2): S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM). RyCarma Therapeutics, Inc.. 2020. ClinicalTrials.gov Identifier: NCT04141670
(baba2024anestheticmanagementof pages 5-5): Hiroko Baba, Ryo Wakabayashi, Hiroki Ichiyanagi, Aki Suzuki, and Nobukazu Sato. Anesthetic management of a patient with central core disease undergoing thoracoscopic lung resection: the importance of neuromuscular monitoring at the masseter muscle. Cureus, Jan 2024. URL: https://doi.org/10.7759/cureus.52456, doi:10.7759/cureus.52456. This article has 1 citations.
(o’connor2023ryr1relateddiseasesinternational pages 11-13): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(raga2024treatmentsforryr1relateddisorders pages 4-5): S Raga, N Voermans, I Perez-Neri, and J Dowling. Treatmentsfor ryr1-related disorders (protocol). Unknown journal, 2024.
(o’connor2023ryr1relateddiseasesinternational pages 8-10): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(godbout2023successfulcorrectionby pages 1-3): Kelly Godbout, Joël Rousseau, and Jacques P. Tremblay. Successful correction by prime editing of a mutation in the ryr1 gene responsible for a myopathy. Cells, 13:31, Dec 2023. URL: https://doi.org/10.3390/cells13010031, doi:10.3390/cells13010031. This article has 20 citations.
(o’connor2023ryr1relateddiseasesinternational pages 10-11): Thomas N. O’Connor, L. R. van den Bersselaar, Y. Chen, Stefan Nicolau, Brentney Simon, Andrew Huseth, Joshua J. Todd, Filip Van Petegem, Anna Sarkozy, Michael F. Goldberg, N. Voermans, Robert T. Dirksen, Leslie Johann Carsten Oliver Razvan Robert James Michael Biesecker Böhm Bönnemann Clarke Cornea Dirksen Dow, Leslie Biesecker, Johann Böhm, Carsten G Bönnemann, Oliver Clarke, Razvan Cornea, Robert T. Dirksen, James Dowling, Michael F. Goldberg, Susan Hamilton, Drew Huseth, H. Jungbluth, Tokunbor A. Lawal, A. Marks, Isabelle Marty, L. Medne, Eva Michael, P. Mohassel, Takashi Murayama, S. Riazi, Anna Sarkozy, Brentney Simon, Joshua J. Todd, Jacques Tremblay, S. Treves, L. R. van den Bersselaar, Filip Van Petegem, N. Voermans, and N. Witting. Ryr-1-related diseases international research workshop: from mechanisms to treatments pittsburgh, pa, u.s.a., 21-22 july 2022. Journal of Neuromuscular Diseases, 10:135-154, Jan 2023. URL: https://doi.org/10.3233/jnd-221609, doi:10.3233/jnd-221609. This article has 10 citations and is from a peer-reviewed journal.
(cacheux2015functionalcharacterizationof pages 1-3): Marine Cacheux, Ariane Blum, Muriel Sébastien, Anne Sophie Wozny, Julie Brocard, Kamel Mamchaoui, Vincent Mouly, Nathalie Roux-Buisson, John Rendu, Nicole Monnier, Renée Krivosic, Paul Allen, Arnaud Lacour, Joël Lunardi, Julien Fauré, and Isabelle Marty. Functional characterization of a central core disease ryr1 mutation (p.y4864h) associated with quantitative defect in ryr1 protein. Journal of Neuromuscular Diseases, 2:421-432, Nov 2015. URL: https://doi.org/10.3233/jnd-150073, doi:10.3233/jnd-150073. This article has 25 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Overview (what is the disease?)

1.2 Key identifiers and ontology mappings

1.3 Synonyms / alternative names

1.4 Evidence provenance

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

Genetic risk factors

Environmental/iatrogenic risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core phenotype spectrum

3.2 Frequencies, onset, severity, progression

3.3 Quality of life impact

3.4 Suggested HPO terms

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Pathogenic variant classes, hotspots, and example alleles

4.3 Functional consequences (mechanistic genotype → phenotype)

4.4 Modifier genes / epigenetics

5. Environmental Information

5.1 Environmental and lifestyle contributors

5.2 Infectious agents

6. Mechanism / Pathophysiology

6.1 Core mechanistic concept: ECC and Ca2+ dysregulation

6.2 SOICR (store overload-induced Ca2+ release)

6.3 SOCE and Ca2+ entry pathways

6.4 Mitochondrial depletion and core pathology

6.5 Suggested ontology terms

7. Anatomical Structures Affected

7.1 Primary organs/systems

7.2 Tissue/cell level

7.3 Subcellular level

7.4 Localization (imaging-guided)

8. Temporal Development

8.1 Onset

8.2 Progression

8.3 Critical periods

9. Inheritance and Population

9.1 Epidemiology

9.2 Inheritance patterns

9.3 Demographics

10. Diagnostics

10.1 Clinical tests

10.2 Imaging

10.3 Biopsy

10.4 Genetic testing

10.5 Malignant hyperthermia testing

11. Outcome / Prognosis

12. Treatment

12.1 Standard of care and supportive management

12.2 Perioperative management (real-world implementation)

12.3 Pharmacologic/interventional evidence and trials

12.4 MAXO suggestions

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Figure evidence (imaging + biopsy)

Recent developments and expert analysis (2023–2024 emphasis)

Limitations of retrieved evidence